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Abstract
This thesis will examine the use of Raman spectroscopy (RS) to probe biomolecular information from
biological samples. The research is comprised of two main studies, a prostate cancer study and a
Streptomyces bacteria study. The prostate cancer study used live cell samples from two different pa-
tients (H517–15 and H554–15), containing normal and Gleason seven cancer cells and two standard cell
lines, PNT2–C2 (normal) and P4E6 (Gleason four cancer). The Raman spectra of each cancer/normal
matched pair were analysed using principle component analysis (PCA). PCA was able to distinguish
the normal cells from the cancer cells for the H517–15 and standard cell line samples. However, the
H554–15 cancer and normal cells comparison proved to be too similar for PCA to separate. Peak inten-
sity ratio (PIR) analyses were used to probe biomolecular differences between the normal and cancer
cell samples. PIR results for the H554–15 sample showed that the cancer and normal cell samples were
similar. PIR results for H517–15 revealed several biomarkers, which are consistent with the biological
literature on cancer. The PIR results for the standard cell lines suggested that the samples may not be
representative of patient biology due to the PIR biomarkers showing opposite trends to both the H517–
15 primary patient sample, and the literature. The second aim of this research was to assess changes
in lipid content between three samples of Streptomyces bacteria. The three bacteria samples comprised
the wild type (J1929), a strain which had undergone a mutation causing a loss of intrinsic antibiotic
resistance (DT3017), and a treated form of the mutated strain (PDT16). The Raman study in this work
corroborated known biological information about the samples, showing an increase in unsaturated fatty
acid (lipid) content from the J1929 sample to the DT3017 sample, followed by a recovery to the J1929
lipid content, upon treatment, for the PDT16 sample.
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Chapter 1
Introduction
1.1 Raman Spectroscopy
Raman spectroscopy (RS) is a label free method for assessing molecular and structural information from
a variety of materials. The Raman effect was discovered in 1928 by Indian physicist Sir Chandrasekhara
Venkata Raman [2] and has been employed extensively across many areas of science. The Raman
effect involves the inelastic scattering of monochromatic light, based on the polarizability of vibrating
molecules. Small differences in the outgoing and incident light energies provides sensitive spectroscopic
information and a molecular scale fingerprint of matter [3].
When light is scattered it is mostly at the same wavelength and frequency as the incident light.
This is known as Rayleigh, (elastic) scattering [4]. A second type of scattering is Raman scattering,
which is much weaker. Raman scattering contributes only 1 in 1010 of the scattered of photons [5] with
frequencies ν0 ± νr, where ν0 is the frequency of the incident light and νr is the shift in frequency due to
molecular interaction in the sample. This Raman shift is referred to as Stokes shift when energy is lost
by the photon or an anti-Stokes shift when energy is gained (Fig. 1.1) [6]. Since the same information
can be obtained from both Stokes and anti-Stokes scattering, it is convention to only measure the Stokes
scattered photons. As the population of molecules in the vibrational energy ground state is greater than
in the excited state according to the Maxwell Boltzmann distribution, Stokes scattering also results in
a more intense spectra, (Fig. 1.2) [7].
1
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Figure 1.1: Energy level diagram showing the Raman effect: Elastic, Rayleigh scattering,
Stokes scattering, where a photon of light loses energy to the moleculal bond and anti-Stokes
scattering, where the photon gains energy from the molecular bond, Ferraro (1994).
Figure 1.2: Diagram of Raman spectra showing the difference between Stokes and anti-Stokes
shifting, Ferraro (1994)
A Raman shift occurs when the electron distribution surrounding a bond in a molecule is distorted
by an incident photon. Following the scattering of the photon the bond returns to its natural state [8].
Classically, the electric field strength (E ) of an electromagnetic wave, in this case, laser light, varies
with time (t) according to
2
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E = E0 cos(2piv0t), (1.1)
where E0 is the maximum vibrational amplitude and v0 is the laser frequency. For the case of a diatomic
molecule, the photon re-emission causes the bond to become temporarily polarised, inducing a dipole
moment (P), where
P = αE = αE0 cos(2piv0t) (1.2)
Here, α is a constant of proportionality known as the polarizability. If a molecule is vibrating at frequency
vm, then the nucleus is displaced by q, given by
q = q0 cos(2pivmt), (1.3)
where q0 is the maximum vibrational displacement. The polarizability (α) can be written as a linear
function of q, for small vibrational displacements. Thus,
α = α0 + (
δα
δq
)0q0 (1.4)
where α0 is the polarizability at equilibrium and (
δα
δq )0 is the rate of change of the polarizability with
respect to the change in nuclear displacement, at q=0. Hence, using Eq.1.4 in Eq.1.2 we can write
P = αE0 cos(2piv0t)
= α0E0 cos(2piv0t) + (
δα
δq
)0qE0cos(2piv0t)
= α0E0 cos(2piv0t) + (
δα
δq
)0q0E0 cos(2piv0t) cos(2pivmt)
= α0E0 cos(2piv0t) +
1
2
(
δα
δq
)0q0E0(cos(2pi(v0 + vm)t) + cos(2pi(v0 − vm)t)).
(1.5)
The first term in this expression represents Rayleigh scattering, or light radiated from a dipole with
frequency v0. The second term represents the Raman scattered frequency shifts v0 + vm (anti-Stokes)
and v0 - vm (Stokes). From this expression, we can determine that a vibration is only Raman active
when ( δαδq )0 is not equal to zero, or in other words, the rate of change of polarizability must not be
zero [6].
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A Raman spectrum is a plot of the scattered light intensity, measured in counts per given time
frame against the wavenumber shift of the scattered photons. The wavenumber (vˆ) is defined in units
of (cm−1) such that
vˆ =
v
c
=
1
λ
(1.6)
where v is the frequency and c is the speed of light and λ is the wavelength.
Raman spectra are therefore characterised by frequency differences between the incident light and
the Raman scattered light, or equivalently, by the Raman shift. The peaks which appear in Raman
spectra can therefore be associated with molecular bonds or functional groups in the sample [6] [9] [10].
As an example, Fig. 1.3 shows some typical Raman spectra for prostate cancer cells [11].
RS is fundamentally different to infrared spectroscopy, despite it also being a vibrational spectroscopy
method. IR spectroscopy requires the molecular vibrations to be associated with changes in a dipole
moment, as opposed to RS being associated with a change in polarizability [12]. One of the major
disadvantages of IR spectroscopy is that simple symmetrical molecules, e.g. N2, are not IR active.
However these molecules can still be probed using Raman spectroscopy due to the molecule having a
single vibrational band [12].
RS has been used to characterise various sample types, both biological and non-biological. Examples
of the use of RS include, the characterisation of carbon, [13] [14] [15], the forensic analysis of illegal
drugs [16] [17] [18] and the characterisation of biological samples.
1.2 Raman Spectroscopy as a Biological Tool
The collection of Raman spectra can be performed in vitro, ex vivo or in vivo with minimal disruption
to the biological sample. This is a major advantage of RS, as most biological assays use chemical
biomarkers and usually require conditions non-native to the biological environment [3]. RS can also be
used on living cells to produce spectra that contain information which is better representative of the
cell’s biology [19].
RS on biological samples produces a fingerprint containing detailed biomolecular information. For
the majority of biological samples, RS spectra are usually split into two regions: the Raman finger-
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Figure 1.3: An example of typical prostate and prostate cancer Raman spectra taken from
Crow et al. (2003). These spectra are averages taken from approximately 200 individual spectra
from a benign prostate hyperplasia (BPH) and prostate cancer tissue samples. Both spectra
have been normalised against the intensity of the 1443 cm−1 peak, which is related to proteins
and lipids.
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print region, between 600 and 1800 cm−1 and the high wavenumber region from approximately 2700-
3100 cm−1. The fingerprint region comprises of a complex representation of molecular vibrations from
DNA/RNA, proteins and lipids [10]. Due to the complex nature of this region, it is often difficult to
extract information from spectra without precise analysis as many peaks overlap and convolve. The
high-wavenumber region is dominated by signatures for various CH bonds commonly associated with
fatty acids and lipids [10]. The portion of the spectra between the fingerprint and high wavenumber
regions is void of biomolecular information and is often left out when acquiring data.
As well as analysing individual peaks within the Raman spectra, it is also common to use the
spectra as a whole to discriminate between samples using multivariate analyses, such as a combination
of Principle Component Analysis (PCA) and Linear Discriminant Analysis (LDA) [11] [20] [21]. These
methods first require the raw Raman spectra to be pre-processed, undergoing baseline corrections, noise
removal and normalisation, to ensure that the discrimination is due to the physical characteristics present
in the spectra, not the noise or background profile. PCA is a statistical process whereby the data is
transformed into a set of principle components (PCs) each expressing the maximum variance in the
data set. This transformation is defined such that that the first PC has the greatest possible variance
accounting for as much of the variability in the data as possible. Each successive component, in turn,
then has the next greatest variance possible under the constraint that it is statistically independent to
the previous components. The PCA identifies new variables, the principal components, which are linear
combinations of the original variables. The samples can then be plotted in two or three dimensions using
their projections onto the first two or three principle components, respectively [22]. Linear discriminant
analysis (LDA) is a technique used in statistics to maximise the variance between two groups of variables.
LDA can be combined with PCA, where the values of the PCs are in-putted as variables into the linear
discriminant, in order to maximise any separation between groups of variables. Any analysis done using
LDA must be cross validated, as in Stone et al. (2002) [23] by a method such as leave-one-out, where
each spectrum is removed in turn, the LDA is performed to produce a model and the removed spectrum
is classified using this model. LDA requires a greater level of validation than PCA as it functions to look
explicitly for differences between classes, whereas PCA only looks for linear combinations of variables
to represent the data as a whole [24].
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Another technique which is used to analyse Raman specra is peak intensity ratio (PIR) analysis. PIR
analysis allows the relative intensities of peaks in the spectra to be compared across samples. This allows
for the identification of specific biomolecular differences between samples or groups. Some research has
suggested that, due to the complex nature of biological samples and their spectra, PIR analysis is inferior
to PCA/LDA, owing to the need for individual peaks to be isolated and measured [25]. However, some
considerations, such as the idea that the direction of greatest variance may be of no biological interest,
must be made about PCA. While PCA is a good tool for discriminating variance between samples [20],
PIR analysis has been used to elicit specific biomolecular markers for samples under observation [26] [27].
PCA can also be used to inform PIR analysis such that the principle component loadings can provide
the peak locations, which have the greatest variance between samples and these can then be further
interrogated by using the PIR method [28].
The interpretation of Raman spectra is well established. Movasaghi et al. (2007) published a review
of Raman literature on biological samples [10], in which a database of peak assignments correlated to
specific biomolecular bond vibrations was created. This database draws from literature on all kinds of
biological tissues . The Movasaghi et al. review found assesed biomolecular peak assignments across the
literature, allowing the creation of a reliable database from which research groups working on Raman
spectroscopy studies of biological specimens could draw assistance [10].
Relevant to this thesis is a review of Raman spectroscopy studies of bacteria. RS has been used to
monitor changes in populations of E. coli bacteria to great effect. Chan et. al. [29] were able monitor
the proteins expressed by single bacteria cells in real-time by observing markers at 1257, 1340, 1453 and
1660 cm−1, which are known to be characteristic of proteins [10].
A study by Munchberg et al. was able to not only use RS combined with PCA/LDA to differentiate
between E. coli and pseudomonas bacteria, but also to identify samples treated with four different
antibiotics [30]. This study was only able to provide very basic biomolecular explanations for the
PCA/LDA result based on what was already known about the antibiotic treatments, e.g. one antibiotic is
known to impair DNA replication in the cells, so a change in DNA content is expected in the spectra [30].
Rusciano et al. used RS combined with PCA to differentiate between sputum samples taken from
cystic fibrosis patients that had been infected p.aeruginosa or s.aurens bacteria and those who were not
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infected [31]. With some further analysis, PIR or similar, this study could begin to form a biomolecular
picture of the difference between the Raman spectra of each sample. The loading presented for the first
principle component (PC1) in this study has several very distinct features with biomolecular significance,
e.g. lipids, phenylalanine and proteins [10].
Other methods have been applied to the RS study of bacteria and cells, in general. Huang et al.
(2003) were able to perform single cell RS on bacteria samples using an optical trap [32]. This process
involved exposing the sample to high laser power, potentially leading to a significant changes and damage
to the cells [33].
A commonly used technique in the RS study of bacteria and biological systems, in general, is surface
enhanced Raman spectroscopy (SERS) [34]. SERS is a technique where the Raman signal is enhanced
by the plasmonic response of metallic substrates or nanostructures. Although SERS has been applied
to the study of biological systems [35], it does not enhance the signal uniformly and is not considered
to be a label free method.
An important component of any biological system is it’s lipid content. In terms of quantitative
Raman analyses of cells, Wu et al. used lipidomics to study lipid changes in algae cells [26]. They showed
that the peak intensity ratio of the 1650 cm−1 C=C band to the 1440 cm−1 CH2 band (I1650/I1440)
correlates to the degree of lipid unsaturation in extracted lipids from the algae cells [26]. The degree
of unsaturation ratios (I1655/I1440 and I1655/I1294), the lipid chain length ratio (I2930/I2959), and
the total unsaturated fatty acids to total amount of fatty acids (i.e., TUFA/TFA ratio I3015/I2851),
have also been used to study lipid droplets in treated and untreated breast and prostate cancer cells
[27]. Although the peak assignments of other lipid-related peak intensity ratios (i.e., degree of lipid
unsaturation and chain length) relate also to proteins, in the study of whole cells, the TUFA/TFA ratio
considers specifically lipid vibrations [10], and thus can be used to interrogate the fatty acids in intact
cells. The mass unsaturation ratio (I1653/I1447) can vary with both the degree of unsaturation and
the chain length of lipids in the sample, making it a less precise measure of lipid content [27] [26]. The
peaks at 1447 cm−1 and 1653 cm−1 are also convolved with various other peaks assigned to both lipids
and proteins [10] furthering the case against its use as a measure of unsaturated lipid content in intact
cells.
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Lipid content within a sample is commonly analysed using gas chromatography/mass spectroscopy,
but information such as the cellular dynamics and the lipids distribution [27] are lost during the homog-
enization process. These techniques cannot be used in vivo or for live cell studies, but with the latest
techniques, Raman spectroscopy has become a tool for analysing the lipid content of biological samples.
One of the key characteristics of Raman spectroscopy is that it can be used non-destructivly. It is
therefore important to ensure that when performing live cell studies the cells themselves are not adversely
affected by the exposure to laser light [36]. Hence it is necessary to carry out tests to ensure that the
Raman experiment does not interfere with the results by changing or damaging the cells [37] [38]. A
simple test involves taking multiple spectra from the same cell and analysing to determine if there is
any deterioration in spectral quality over time. A more complete test is a ‘Trypan Blue Assay’ [39],
Trypan blue is a dye which only permeates dead or damaged cells [40]. The trypan blue assay is used
in biological research as a cell viability assay, to determine whether a cell culture contains dead cells,
or if a particular procedure has had a damaging effect on a cell culture. It has been applied to live cell
RS by Oshima et al. (2010) [38], who reported that for a 532nm laser with a power of 50mW and an
exposure time of 60 seconds, the trypan blue assay was negative for lung cancer cells. Notingher et al.
(2002) [41] also reported that for a 785nm laser with a power of 115mW and an exposure time of 120
seconds the assay also returned a negative result for lung epithelial cells taken from mice. Both studies
used a trypan blue assay to confirm that RS could be used to study living cells, non-destructively.
Similarly, dried cell samples are also susceptible to the effects of long term exposure to laser light,
although the laser is less likely to radically alter the biology of a dried sample compared to a live
cell sample, there is still a significant risk of burning, characterised by obvious black/brown marks on
the sample, over saturation of the CCD, or by the appearance of broad bands centered at 1500 cm−1
signifying amorphous carbon [42]. This type of damage can be avoided by lowering the intensity of
the laser using a filter and shortening the exposure time of the sample, while still maintaining a strong
enough signal to provide meaningful results [43].
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1.3 Prostate Cancer Cells
Prostate cancer (PCa) is the most commonly diagnosed cancer in men [44]. There are approximately
30,000 new diagnoses every year in the UK alone, which accounts for 23% of male cancers [44]. PCa
results in around 10,000 deaths in the UK every year, giving the disease a mortality rate second only
to lung cancer amongst cancers [45]. While an early diagnosis can lead to a ten-year survival rate of
around 85%, the life expectancy for a patient with advanced PCa can be as low as 12 months [36] [46].
In its early stages PCa is virtually symptomless and only becomes noticeable when the tumour is of a
size large enough to affect the passage of urine to the penis [47].
The current diagnosis methods for PCa include a prostate specific antigen (PSA) test [48], a digital
rectal examination (DRE) [49], or a prostate biopsy, where a physical tissue sample is taken from the
patient for testing. A PSA test simply measures the amount of PSA present in a patients blood, as a
tumour on the prostate causes an increase in its production. However, this test is considered unreliable as
PSA is not specific to cancerous growth. Enlarging or swelling of the prostate can also cause an increase
in PSA in the blood and, in turn, lead to a false positive diagnosis of a tumour. With 78% of test results
later being determined to be false [48]. Physical examinations, as well as being time consuming and
uncomfortable, can also lead to misdiagnoses due to the human element of the procedure [50]. These
factors together provide significant justification to look for new, cost-effective, more discriminatory and
patient friendly methods for interrogating prostate tissue.
The current standard of grading PCa is the Gleason grading system [51]. A Gleason score is given
to a cancer based on the microscopic appearance of the prostate gland patterns, or histopathology, with
a higher score equating to a more aggressive tumour [52]. In general, a lower grade corresponds to
prostate tissue with small, uniform glands [51]. The grade increases as cells become more spread out
and glands only occasionally form [51]. The Gleason grade is a sum of two Gleason scores assigned to
the two most commonly observed gland patterns on an individual prostate by a pathologist [53]. Each
score is from one to five, making the final Gleason grade a number between two and ten. Gleason grades
are often grouped according to similar biological behaviour: (i) low-grade, or ‘well differentiated’, from
two to six, (ii) intermediate-grade at seven and (iii) high-grade, from seven to ten [54].
Early cancer research has suggested that cell metabolism may provide many of the key features
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exhibited by malignant cells [55]. One of the main hallmarks of a cancerous cell is rapid growth and
proliferation. In order to grow and divide at a higher-rate, the cell must develop a degree of autonomy
and does so by a process called de novo lipogenesis [56]. De novo lipogenesis is the conversion of excess
carbohydrates into fatty acids. These fatty acids in turn support the increased need for membranes in
accelerated cell growth and proliferation [57].
Past RS research has found that lipid markers are a valuable tool for discriminating cancer cells
from non-cancerous cells [27] [58]. Relative peak intensities at 1450 cm−1 (CH proteins and lipids)
and 1305 cm−1 (CH bending, CH twisting of protein) have been found to increase for various types
of dysplasia [32] [58] [59]. Such markers indicate higher concentrations of lipid biomolecules within
the cells with, lipid accumulation being thought to be a hallmark of aggressive cancer cells [60]. The
total unsaturated fatty acid to total fatty acid TUFA/TFA ratio (I3015/I2845) was also used in the
literature [27] [61]. A lower TUFA/TFA ratio, or relative unsaturation degree, is indicative of de novo
lipogenesis, which is thought to be a hallmark of malignancy in cells [62] [63]. The unsaturation degree,
however, is not always sensitive enough to provide a distinction between benign and malignant cells, as
in Neiva et al. (2012) [61].
RS peaks at 1000 cm−1 and 1586 cm−1, corresponding to phenylalanine have been proposed by
Huang et al. and Li et al. as markers for malignancy [32] [64]. Both references showed that phenylala-
nine increases in cancer cells [32] [64]. Research by Fu et al. found that melanoma cells are dependent
on phenylalanine as its restriction causes multiple changes in cell behaviour [65].
RS has been used to quantitatively analyse the DNA/RNA expression of malignant cells [66] [58].
The literature suggests that the Raman band at 1335 cm−1 (nucleic acids and proteins [10]) shows
higher relative intensities in cancerous cells compared to normal cells when normalised to the 1447
cm−1 peak [58] [66] and when normalised to the total area under the curve [32]. Raman bands between
721 and 827 cm−1 representing nucleic acids and the DNA backbone are more broadly categorised
as DNA [10]. This region in the Raman spectra shows a similar relationship to that of the 1335 cm−1
peak, in that higher intensities in this region generally correspond to increasingly aggressive tumours [20].
Specifically, the intensity of the DNA peak at 780 cm−1 (phosphate bond, cytosine, thymine) is said to
correlate strongly with malignancy in breast tissue [3]. The peak around 780 cm−1 has also been shown
11
1.3 Prostate Cancer Cells
to decrease dramatically when living lung cancer cells undergo programmed cell death, or apoptosis [19].
Another area in which RS has proven to have significant discriminatory power is the study of proteins
and individual amino acids. Studies have found that aggressive tumours, specifically metastatic tumours,
express greater levels of various proteins [8] [67] shown by the increased relative intensities of peaks in
the Raman spectra at 643, 760, 853, 937, 1000 and 1032 cm−1 [8] [10] [67]. Previous work has been able
to use these bands amongst other protein signals, combined with other peaks in the fingerprint region,
to fully discriminate between malignant and non-malignant cells and tissue samples [67].
Crow et al. [11] and Shetty et al. [68], respectively, found that glycogen, with peaks at 850 cm−1,
934 cm−1 and 1029 cm−1 in the RS spectra, is a marker for malignancy in both prostate [11] cancer and
oesophageal [68]. Both sets of research found that lower glycogen content is indicative of malignancy.
Non-RS research, however, has found repeatedly that cancer cells exhibit higher glycogen concentrations
[69] [70]. This disagreement highlights a key area for RS and this study in that the spectral results must
represent the biology of the cells. Such differences may be caused by low RS sampling, inaccurate
analysis or contaminated or damaged samples. More research is therefore needed to develop the RS as
a biomolecular tool.
The above examples of RS as a means to interrogate cancer cells involve a variety of sample types.
Most of the published research uses standard cell lines, which are immortalised cell lines originally
derived from a specific organ or tumour site. For example, the LNCaP cell line used in some of the
literature [11] [67] was derived originally from a lymph node metastasis of prostate adenocarcinoma
(PCa) and have been used extensively in the field of oncology as a standard [71]. Another example is
the standard cell line PNT2-C2 which comprises cells derived from normal prostate tissue that have been
immortalised so as to act as a control against which malignant cells can be compared [72]. Although
these immortalised cell lines provide a good standard and a high degree of reproducibility, they do not
fully mimic clinical disease [73].
Primary, patient-derived cell lines are cell lines and have come directly from a patient and often
come in matched pairs, i.e. from a tumour and from normal prostate tissue in the same patient.
Primary samples are often more difficult to obtain and maintain, however, they have been shown to offer
advantages over standard cell lines [74] [75]. For example, studies which use primary samples gathered
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from multiple patients allow the researchers to capture the inherent individual and interindividual
heterogeneity of biological tissue [11]. These samples also eliminate the likelihood that the results
obtained are cell line specific as there have been several reports in the literature regarding the mis-
identification and cross-contamination of cell lines [74] [75]. Primary patient-derived samples not only
open the door for techniques such as RS to provide better diagnoses using multivariate analyses, as well
as to provide patient specific information based on individual peak intensity ratio (PIR) analysis. An
important next step for RS is to determine the difference in spectral information between biologically
similar cell lines and primaries, and to ascertain whether, for use in RS, standard cell lines give a
clinically accurate molecular fingerprint of PCa.
1.4 Streptomyces coelicolor Bacteria
As discussed earlier, RS is a powerful technique for analysing a variety of biological samples. One of
the key areas of RS research is in the study of bacteria. Streptomyces coelicolor (S. coelicolor) is a
bacteria belonging to the Streptomyces genus commonly found in soil [76]. This particular strain is
responsible for the production of a large variety of antibiotics for both human and veterinary use [76].
The wider study, which this RS study of S. coelicolor is to be a part of refers to the development of
antibiotic hypersensitive mutants of S. coelicolor [1]. In mycobacteria, polyprenol phosphate mannose
synthase (ppm1 ) is an essential enzyme required for lipomannan biosynthesis where lipomannan is a
major constituent of the cell wall [77]. Mutations in ppm1 lead to increased susceptibilities to multiple
antibiotics, most of which act at different stages of cell wall biogenesis. In the RS portion of this study,
three different strains of S. coelicolor are analysed, a wild type bacteria (J1929), mutant type, that has
a mutation in the ppm1 gene (DT3017) and the mutant type treated with plasmids encoding the wild
type ppm1 gene (PDT16) [78] [79].
RS has been used in the fundamental characterisation of bacteria, for infection diagnostics and in
antimicrobial treatment development [30] [80] [81] [82]. RS has also been used for the specific charac-
terisation of Streptomyces bacteria [80] [83]. Walter et al. (2011) used RS to classify different species of
Streptomyces, noting particularly high variance in the high wavenumber 2700–3100 cm−1. Also conclud-
ing that due to its filamentus nature, classification of Streptomyces bacteria using a single cell approach
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Figure 1.4: An example of Raman spectra of Streptomyces bacteria, from Walter et al. (2012).
Four S. coelicolor Raman spectra are shown. From bottom to top, the un-contaminated sample
and three samples with increasing levels of contamination with Cl- and Ni2+
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cannot be expected to be reliable, hence their use of bulk samples [83]. Walter et al. (2012) used
RS to classify samples of Streptomyces bacteria which had been exposed to different levels of heavy
metal contamination [80]. Fig. 1.4 shows an example of Raman spectra taken from Streptomyces bac-
teria by Walter et al. [80]. This figure shows four Streptomyces Raman spectra. From bottom to top,
the un-contaminated sample and three samples with increasing levels of contamination with Cl- and
Ni2+ [80].
Studies have verified Ramans ability to not only discriminate bacterial species, but also its sensitivity
to distinguish at the sub-species level as well [83]. RS is especially useful as a tool for characterising
bacteria as it requires no invasive preparation, which can lead to contamination and altered findings [84].
In this work, the TUFA/TFA lipidomic ratio is used for the first time to determine changes in the
lipid content of J1929 (wild), PDT16 (treated) and DT3017 (untreated, ppm1 mutant) S. coelicolor cell
lines. These results will inform the larger biological study of any changes in lipid membrane composition
(unsaturated to total fatty acids) between the three bacteria types. It is expected that the wild type and
treated mutant type should have a similar lipid content, whereas the untreated mutant type will have
undergone a change in membrane composition, therefore a change in lipid content and hence TUFA/TFA
ratio is anticipated.
1.5 Summary of Research Objectives
This work will examine RS as a tool for interrogating biological cells. Drawing on previous work in the
field of PCa research, this project will examine the use of both PIR analyses and PCA/LDA as tools for
determining the molecular composition of prostate cancer and normal prostate samples. These data will
be tested for their ability to discriminate not only tumour samples from normal tissue samples, but also
to assess patient-specific information from patient derived primary cell culture samples. Alongside these
investigations there will also be a critical analysis of the use of standard cell lines in RS for cancer research
compared to the use of primary samples. The RS analyses will also be applied to the study of S. coelicolor
bacteria. Considered by this work will be the use of RS as a tool for discriminatory characterisation of
S. coelicolor bacteria to a sub-species level, specifically the ability of RS to discriminate between three
strains of S. coelicolor bacteria having undergone a mutation and subsequent gene treatment. This is to
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determine the effect the mutation and gene treatment have on the lipid composition of the S. coelicolor
bacteria.
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Chapter 2
Methods
2.1 Prostate Cancer Cell Culture
The two patient-derived primary cell culture samples used in this research are labelled H517-15 and
H554-15. These samples are both matched pairs meaning that both normal and cancer samples were
taken from the biopsies of each patient. As determined on histropathology, the normal samples are
representative of normal prostate tissue and the cancer samples are Gleason seven graded meaning
the cancer is of intermediate aggressiveness [51] [52]. In general, the location of prostate tumours is
determined by MRI, with the pathologies diagnosed by needle biopsies prior to surgery. On the day
of the surgery, either a transurethral resection of the prostate (TURP), or a radical prostatectomy is
performed, the latter involves the removal of the entire prostate. The tissue procurement officer collects
the prostate tissue from the surgeon in the operating theatre and takes two needle punch biopsies, one
from a normal area and one from the tumour site. Only samples where the tumour is palpable are
used. In addition to the pathologies on the needle punch biopsy samples, confirmatory pathology is
also performed on the the sites surrounding the biopsies to ensure accuracy in the final diagnosis of the
samples [85]. After a sample is collected from surgery it in is placed into a transport medium (RPMI
Medium 1640 plus 10% fetal calf serum, 2 mM l-glutamine, and 1% ABM (antibiotic/antimycotic)).
These samples are then delivered to the Cancer Research Unit (CRU) at the University of York, and
then processed according to the Unversity of York CRU published protocols [85] [86] [87] before being
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frozen in liquid nitrogen for storage.
The two standard cell lines used in this research are P4E6 and PNT2-C2, which are thought to be
representative of cells from a Gleason four tumour and a normal prostate sample respectively [72] [88].
While the P4E6 cell line is of a lower Gleason grade than the primary samples used in this study, the
consensus in the literature is that cancer specific biomarkers apply to a range of stages. Crow et al.
(2003) observed that for all cancers (Gleason less than seven, Gleason seven and Gleason greater than
seven), when compared to normal prostate cells, show the same trends [11]. It is therefore hypothesised
that when compared to its normal match, the P4E6 cell line should match the trends seen for the primary
sample pairs. The PNT2–C2 normal sample is taken from normal prostate tissue and is therefore most
closely representative of the primary normal samples used in this study and can thus be used to compare
direct patient-derived primary culture cells and standard cell lines.
All of the cell culturing in this study was performed in a sterile environment under a fume hood
at the University of York CRU. Both the primary cell cultures and standard cell lines, were frozen in
liquid nitrogen for storage.
Prior to RS analysis, the cell sample is mixed with growth media and put into a T25 flask to be split.
The growth media is different depending on the cell line. The P4E6 cell line requires K2 media, which
comprises KSFM, supplements, 2% FCS and L-glutamine. The PNT2–C2 cell line requires R10 media,
which comprises RPMI, 10% FCS and L-glutamine. Finally, the primary patient samples are cultured
in stem cell media (SCM), which comprises KSFM, supplements, GM-CSF, cholera toxin, SCF, LIF and
L-glutamine. Half of the cell sample is then re-frozen to later use again, while the other half of the cell
sample is placed back into a T25 flask together with fresh growth media and incubated at 37◦C. The
growth media for each cell sample is replaced with fresh media every two to three days. Cell preparation
must begin at least two days prior to RS analysis. Two days prior to RS analysis the growth media is
removed from the T25 flask containing the growing cells and the remaining cells are then washed with
3 ml of phosphate buffered saline (PBS). 1.5 ml of trypsin is then added to separate the cells from the
flask and following this the flask is then incubated for a few minutes at 37◦C. At this point the flask is
then inspected to check that the cells are coming off it, and once achieved, they are then re-suspended
in 5 ml of growth media.
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From the cells and media solution, 10 µl of cells is then used in a haemocytometer to determine
the number of cells per unit volume for plating. For a CaF2 disc, 13 mm in diameter and 1 mm thick,
placed into a 35mm petri dish, 50,000 cells had to be plated to achieve a good degree of cell confluence.
Once plated onto the CaF2 disc, an appropriate amount of growth media is then added to the petri
dish containing the disc (2.5 ml for a 35 mm petri dish) together with antibiotic/antimycotic (ABM) to
prevent cell contamination. The plated CaF2 disc and petri dish are then incubated for 24 hours. The
next day the media in the petri dish is changed to starvation media, which is the growth media minus
the nutrient serum, i.e. K2 and SCM starvation medias are just KSFM, and the R10 starvation media
is just RPMI. Starving the cells synchronises them into the G0 (resting) state of the cell cycle as RS has
been shown to be sensitive to cell cycle changes [89]. On the day of the Raman analysis the CaF2 disc
and petri dish are washed twice in Hanks balanced salt solution (HBSS), and fresh HBSS (2.5 ml) is
added. HBSS is used as is keeps the cells from drying out, as well as adding minimal background signal
to the Raman spectra [38].
2.2 Streptomyces coelicolor Cells Culture
S. coelicolor cell line Description
J1929 (wild) Wild type S. coelicolor bacteria.
DT3017 (untreated)
S. coelicolor bacteria with a mutation in the ppm1 gene,
causing a decrease in intrinsic antibiotic resistance.
PDT16 (treated)
The mutant type bacteria after treatment with plasmids en-
coding the ppm1 gene. This treatment is designed to reverse
the effects the mutation has on the antibiotic resistance of
the S. coelicolor bacteria.
Table 2.1: Table showing the three samples and their descriptions [1].
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All bacteria culturing methods for the S. coelicolor cells have been adapted from the procedure set out
in Kieser et al. (2000) and summarised here [90]. All cell culturing here was performed in Prof. Maggie
Smith’s lab, at the University of York, by Dr Nicholas Read and Dr Robert Howlett. The following
process is identical for each of the three strains to be analysed in this study, detailed in Table. 2.1. A
dense bacteria spore suspension (500 µL c.1010 spores per ml), of one of J1929, PDT16 or DT3017, is
heat-shocked at 50◦C for ten minutes in 10 ml TES (0.5 M pH8), then cooled under cold tap water.
The bacteria culture is then added to 10mL double-strength germination medium in a 250 ml baﬄed
conical flask and shaken at 37◦C at 180 rpm for 8 to 9 hours. The double-strength germination medium
comprises Difco yeast extract, 1 %, Casaminoacids, 1 %, CaCl2, 0.01 M, and is prepared and autoclaved
separately as a 5 M solution. The bacteria culture is then spun down and suspended in 10 ml Difco
nutrient broth. The OD450nm is measured and the culture diluted in Difco nutrient broth to obtain 40
ml with an OD450nm of 0.05.
The 40 ml culture is then grown in a 250mL baﬄed flask at 30◦C for 12 to 13 hours, after which 10
ml is taken for dry weight measurements. To dry the culture, it is spun down, washed and spun down
again with the resulting pellet put into a pre-dried tube. The remaining 30 ml of the bacteria culture
is spun down and washed with MilliQ water ready for plating.
Cell samples from each of the J1929 (wild), PDT16 (treated) and DT3017 (untreated, ppm1 mutant)
bacterial cultures were washed in high-purity deionised water to remove the bacterial culture media
and then plated via pipette-deposit directly onto small CaF2 disks (13 mm diameter and 1mm thick).
Bacteria were then gently spread over the disk surface with excess water removed by pipette aspiration.
The samples were air-dried in a fume cupboard in preparation for Raman analyses.
2.3 Raman Spectra Acquisition
The Raman laser spot size (d l) for any optical system is given by
dl =
1.22λ
NA
(2.1)
where λ is the laser wavelength and NA is the numerical aperture of the objective lens [6] [7].
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Figure 2.1: The Horiba XploRA instrument used for all of these experiments.
Figure 2.2: Basic flow schematic of a typical confocal Raman spectroscopy set-up, represen-
tative of this experimental set-up.
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From the equation for lateral resolution,
∆x =
0.61λ
NA
(2.2)
it can be seen that the shorter the wavelength of the laser (λ), the higher the resolution will be, where
∆x denotes the smallest resolvable distance between two points and NA is the numerical aperture of
the objective lens [6].
The values for the following parameters on the Horiba XploRA Raman instrument (Fig. 2.1) which
were used in these studies will be given in the relevant sections. Fig. 2.2 shows a flow schematic of the
Raman instrument used in this study. The grating in the spectrometer disperses the Raman signal onto
the CCD detector by deflecting each wavelength at a different angle. A higher number of grooves/mm
in the spectral grating results in a greater spectral resolution [91]. The hole setting on the Raman
refers to the confocal hole, which is used to define the resolution depth of the measurement. A larger
hole allows more than one focal plane of the sample to be measured, resulting in a greater intensity in
the signal [91]. However, for thin samples this may result in unwanted readings from other materials
such as the microscope slide. For the Raman experiments in this thesis, only confocal settings were
used, meaning spectra were only taken from single focal planes. The ‘slit’ setting is used to change
the spectral resolution of the measurement where a greater slit width results in a decrease in spectral
resolution [6] [91].
Two types of corrections were performed as part of Raman measurement acquisition. When the
intensity correction system (ICS) is turned on, a correction factor is applied to the spectrum so that
measurements taken with different Raman acquisition settings yield the same results. When the dark
correction is switched on, it subtracts a pre-determined dark file is subtracted from the spectrum cor-
recting for the detector response and pixel variation.
To control the incident laser power at the sample and therefore avoid sample damage a neutral
density filter was used.Raman measurement accumulations could also be set to acquire multiple accu-
mulations of spectra data and to average them in order to improve the final spectral quality.
Before spectra were acquired a wavenumber calibration using a silicon reference sample was per-
formed. After bringing the silicon reference into focus under the 100x objective lens (numerical aperture
= 0.9), Labspec calibrated all lasers and gratings automatically [91]. To check the alignment of the
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laser, an ink spot was drawn on to a glass microscope slide using a dry wipe marker pen. The laser was
then used to burn a small part of the ink away. This burn mark was then viewed optically and aligned
with the cursor on the video display.
2.4 Trypan Blue Assay
In order to confirm that extended exposure to the laser has not damaged the cells a, trypan blue assay
was performed [38]. An image was taken of three individual cells before exposure to any laser light with
the cell locations recorded using the x-y-z motorised stage. Raman spectra were then collected on each
of the three cells and after this optical images were then taken. The HBSS was then removed and a
0.4% solution of trypan blue dye was added to the disc and allowing time to enter any damaged cells.
The trypan blue was then gently washed away using HBSS before more HBSS was added back to the
plate. Optical images were then taken of each of the three cells to confirm that they were undamaged.
As a control, the cells were then killed with ethanol and a second trypan assay performed to ensure that
the trypan was functioning as intended [39].
2.5 Raman Measurements of Prostate Cancer Cells
All live cell experiments on the H517–15 and H554–15 primary patient derived cancer and normal
pairs, PNT2–C2 normal and P4E6 cancer standard cell lines were performed under the same conditions
using the same acquisition parameters. Individual cells were measured using the HORIBA XploRA
micro-Raman instrument with 532 nm laser-light, 63x dipping lens (NA=1) and 2400 lines/mm spectral
grating. All measurements were made in the confocal mode using a slit of 200µm and a hole of 100µm.
A resulting laser spot size of approximately 1µm was used with a 50% filter, resulting in 3.5mW laser
power at the sample. As the laser light permeates HBSS, it is likely that the power at the sample is
even further reduced. With these equipment settings the Raman microscope has a spectral resolution
of 1 cm−1 and lateral resolution of 0.3 µm.
Spectra were acquired in the 600–1800 cm−1 (fingerprint) region and the 2700–3100 cm−1 (high-
wavenumber) region, using HORIBA LabSpec 6 software, with an acquisition time of 45 seconds averaged
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over two spectral accumulations. Between 150 and 170 spectra were acquired per cell type, with these
spectra then averaged to obtain a single representative spectrum for each cell sample. Each single
spectrum was taken from a new, randomly selected individual cell nucleus, with great care taken not to
analyse the same cell more than once to avoid over exposure to the laser.
2.6 Raman Measurements of Streptomyces coelicolor Bacteria
Raman point measurements were performed on randomly selected S. coelicolor cells in the J1929 (wild),
PDT16 (treated) and DT3017 (untreated) populations using a HORIBA XploRA micro-Raman in-
strument with 532 nm laser-light, x100 objective (0.9 NA) and 2400 lines/mm spectral grating. All
measurements were made in the confocal mode using a slit of 200 µm and a hole of 100 µm. The laser
spot size was approximately 1 µm, and with a 50% filter, this resulted in a 3.5 mW laser power at the
sample. Using these equipment settings the Raman microscope has a spectral resolution of 1 cm−1 and
a lateral resolution of 0.4 µm.
Spectra were collected using the HORIBA LabSpec 6 software in the 600–1800 cm1 fingerprint region
and the 2750–3110 cm1 high-wavenumber region. Each individual spectrum was obtained using a 90
second acquisition time averaged over two spectral repetitions. Between 40 to 55 spectra were randomly
collected across the population of each cell line. With these spectra then averaged to obtain a single
representative spectrum of each sample.
2.7 Prostate Cancer Spectra Analysis
All the spectra analysis was performed using IGOR Pro 6.35. The Average waves package in IGOR Pro
was used to create an average spectrum and standard error of the mean (SE) wave from each data for
each cell line. All of the peaks in the average spectrum and SE wave were then fitted using the package
multipeak fitting 2 (MF2). The fitting using the MF2 package involved first performing a linear or cubic
baseline correction to the individual peak or cluster of peaks (if convolved) before assigning a Gaussian
profile to the peak locations Fig. 2.3. From this baseline and fitted Gaussian peak(s), the peak heights
were then determined. For display purposes, a linear baseline correction was also performed across the
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Figure 2.3: An example use of the multipeak fitting package to fit a highly convolved part
of a spectrum. The example here is the H517–15 cancer sample between 2700 and 3100 cm−1.
This region contains the peaks, 2850, 2871, 2893, 2937, 2970, 3008 and 3065 cm−1. The figure
shows the averaged spectrum, Gaussian peak profiles and cubic baseline.
whole spectra using The Raman Toolset software [92]. Normalisation was also performed against the
1447 cm−1 peak for direct comparison of the spectra [11].
Principle component analysis (PCA) followed by linear discriminant analysis (LDA) analysis was
performed on all six samples using the statistical package R v3.3.0. LDA was only used on the six
samples combined to maximise the variance and achieve separation between the cell types. The cell
separations were validated using leave one out cross validation [11], whereby each inividual spectrum is
left out of the LDA model in turn, before being classified using the groups returned by the model. This
process is repeated for each and every spectrum in order to generate a picture of the overall accuracy of
the LDA model on these data sets. Kaiser’s criterion, which states that on a standardised dataset only
principle components (PCs) with a variance greater than one are significant [93], was used to determine
the number of PCs for LDA. For the sample pair comparisons, only PCA was required to achieve the
maximum possible separation of the samples.
Before loading the spectra into R, each individual spectrum was first linear baselined and normalised
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to the total area under the curve, using the Raman toolset, to ensure that the variances picked up by the
algorithm correspond to biomolecular differences and not to artefacts from the spectral acquisition. The
loadings of the principle components responsible for separating the samples were analysed to determine
regions in the spectra of greatest variance. These results could then be used to inform a deeper analysis
of the peak intensity ratios of those areas [28].
To ensure sufficient data has been collected, SE waves were produced each time five more spectra
were added to the average. As the number of spectra approached the maximum number collected
for each cell line (between 150 and 170 spectra) it was expected that the SE wave would converge.
This process of testing the SE convergence was repeated for both the fingerprint and high wavenumber
regions. To ensure solid statistics in the analyses, peak intensity ratio (PIR) convergences were are also
performed as a function of the number of spectra in the spectral average for each cell line.
The unsaturation ratio (I1447/I1663) and the TUFA/TFA, or total unsaturated fatty acid to total
fatty acid ratio (I2850/I3008) were selected to show the statistical convergence as they have been pre-
viously shown in the literature to differentiate between normal and cancer cell samples [27] [61]. The
convergence of the percentage SE of these ratios was also calculated as a function of the number of
spectra in each spectral average as a means of establishing data convergence. When directly comparing
PIRs a T-test was performed to ensure validity, as in Oshima et al. 2010 [38].
The SE in the PIRs were calculated using the values from the SE wave, according to
dz = z
√
(
dx
x
)2 + (
dy
y
)2 (2.3)
where x and y are the peak intensities, z is the PIR and dx, dy and dz are their associated standard
errors [7].
2.8 Streptomyces coelicolor Spectra Analysis
The averaged spectrum for each cell line was baseline-corrected from the first to the last spectral point
in the fingerprint and high-wavenumber ranges using the ‘Raman tool set package [92]. Peak regions
in the acquired spectral ranges were then linear baseline-corrected and Gaussian peak-fitted using the
software package IGOR Pro 6.35. The peak fittings were used to obtain the average peak positions
26
2.8 Streptomyces coelicolor Spectra Analysis
measured across the cell-lines. Individual peak identifications were made by correlating the average
peak positions with literature references [10] [80]. The total unsaturated fatty acid to total fatty acid
(TUFA/TFA) peak intensity ratio (I2850/I3008) for each cell line was determined from each averaged
spectrum, with its uncertainty calculated from the SE uncertainties in the measured TUFA and TFA
peak intensities. The SE in the ratio was then calculated using Eqn.2.3. To ensure sufficient number of
spectra was collected to represent each sample population, the convergence of the percentage standard
error of the mean (SE) of the TUFA/TFA ratio was calculated as a function of the number of spectra
in each spectral average.
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Chapter 3
Results and Discussion
3.1 Raman Spectroscopy Studies of Prostate Cancer and Nor-
mal Prostate Cells
This section of the study aims to use Raman spectroscopy to analyse biomolecular differences between
normal and cancerous prostate cells. Firstly, principle component analysis and linear discriminant
analysis were used to separate the samples and provide a basis for deeper spectral analysis via the
loadings of the principle components. Using examples from the literature and information from the
loadings of the principle components, peak intensity ratio analysis was used to gather the information
on the biomolecular differences between the normal and cancer samples presented in their spectra.
Aside from critically analysing the use of RS in cancer research, this study will also observe and critique
the use of immortalised standard cell lines to represent patient biology by comparing the biomolecular
information presented by patient samples and standard cell lines.
Six cell line samples were used in this study comprising three normal and three cancer samples. These
samples consist of the H517–15 and H554–15 primary patient samples (Gleason 7 cancer and normal
matches), the P4E6, Gleason 4, prostate cancer cell line and the PNT2–C2 normal prostate standard
cell line. The H517–15 and H554–15 primary patient cancer samples were both graded Gleason 7 at
first histopathology.
Using principle component analysis (PCA) this study was able to differentiate normal from cancer
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cells for both the H517–15 primary and P4E6/PNT2–C2 standard cell line pairs. However, this study
was not able to differentiate normal from cancer for the H554–15 primary patient samples.
Peak intensity ratio (PIR) analysis undertaken by this study was able to identify several cancer
biomarkers for the H517–15 primary sample, consistent with the literature on cancer and normal cells.
Some of these biomarkers include lipids, glycogen, phenylalanine and DNA/RNA. PIR analysis cor-
roborated the finding from PCA in that the H554–15 cancer and normal samples are biomolecularly
similar. Differences in these samples were found in the heavily convolved peaks related to DNA, lipids
and proteins with these being the only discriminatory markers for this sample. Although separated by
PCA, the picture with the standard cell lines is less clear. Some markers for these cell lines (e.g. total
unsaturated fatty acids against total fatty acids (I2850/I3008)) are corroborated by the literature, some
are not (e.g. phenylalanine (I1000/I1447)), bringing forth the question as to whether these cell lines
provide an accurate representation of patient biology.
3.1.1 Trypan Blue Assay
In order to prove that exposure to laser light does not cause damage to these cells, a trypan blue assay
was performed [39]. Notingher et al. (2002) performed a trypan blue assay as part of the first ever
live cell RS study [41]. The trypan blue assay in this study was performed on the P4E6 standard cell
line, which was chosen due to the limited availability of primary samples for this study and the relative
abundance of standard cell lines. RS is well documented in the literature as being non-destructive to
single cells [26] [94], at much greater laser exposures than that used in this study. Hence, a trypan blue
assay would be a definitive check on the non-destructive testing used in this work.
The results of the trypan blue assay are shown in Figs. 3.1–3.3. The optical images show the single
cell that was tested using this procedure (in the red square). This test was also repeated for a further
two cells yielding the same result. In Fig. 3.1 the first cell is shown before any exposure of it to laser
light or dye. The cells that were selected for this assay display no visual abnormalities or contaminations
as per the selection criteria for all cells in this study. Fig. 3.2 shows the same cell after exposure to
laser light under the same conditions as used for Raman measurements, as outlined in the methods
section, and the addition of trypan blue dye. In the case that the exposure had caused damage to the
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cell, the dye would have been uptaken by the cell. As there was no uptake of the dye by the irradiated
cell, Fig. 3.2 therefore confirms that laser exposure, at the power and acquisition time used for Raman
measurement in this study, does not cause damage to the cells.
Fig. 3.3 shows the result of a second trypan blue assay where the cells have first been killed with
ethanol before the dye is added. In this case, the dye was uptaken by the damaged cells, therefore
confirming the result of the first assay where no cell damage occurred. Based on these results, it can
therefore be concluded that the Raman spectra obtained in this work provide a fingerprint of unmodified
living cells. This result is supported by literature on the use of trypan blue assays to determine cell
viability, for example, Strober (2001) [40]. Similar results were shown in other RS studies which also
used trypan blue to assess cell viability after exposure to laser light. Oshima et al. (2010) [38] reported
that for a 532nm laser with a power of 50mW and an exposure time of 60 seconds, the trypan blue assay
was negative. Notingher et al. (2002) [41] also reported that for a 785nm laser with a power of 115mW
and an exposure time of 120 seconds the assay also returned a negative result.
Fig. 3.1 shows a cell in the lower right of the image which disappears in Figs. 3.2 and 3.3. It is
likely that this cell was not properly attached to the surface of the disc, and therefore was easily washed
away when the trypan dye was removed. It is unlikely that its disappearance is a result of any laser
exposure, as the laser spot size is approximately 1µm.
3.1.2 Raman Spectra
The averaged Raman spectra for the direct patient derived primary cell cultures, H517–15 cancer
(n=164), H517–15 normal (n=161), H554–15 cancer (n=156), H554–15 normal (n=167) and the P4E6
cancer (n=149) and PNT2–C2 normal (n=154) standard cell lines (Figs. 3.4 and 3.5) are consistent
with previously published spectra of prostate cancer and normal prostate cells [11] [20] [27] (see also
Fig. 1.3), as well as human cancer cells [27] [95], in general, where the spectra have been taken from
the cell nuclei. Here n refers to the total number of single spectra obtained for each cell line. Figs. 3.4
and 3.5 show the averaged spectra for each cell line after being linear baselined and normalised to the
peak at 1447 cm−1. The normalisation to the 1447 cm−1 peak follows Crow et al. (2003) [11], Chan et
al. (2009) [96] and Krafft et al. (2012), where the peak at 1447 cm−1 was used to normalise prostate
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Figure 3.1: Optical image obtained using a 63x dipping lens with a numerical aperture of one
showing the P4E6 cell (inside the red square), which was analysed before laser exposure or the
application of the trypan blue dye. The cell chosen is of a regular size with no obvious defects
or contaminations.
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Figure 3.2: Optical image obtained using a 63x dipping lens with a numerical aperture of
one of the same P4E6 cell (inside the red square) after laser exposure and the addition of the
trypan blue dye. Trypan blue is a dye which is only taken up by cells that have damaged outer
membranes. In this case the dye has not been uptaken by the cell indicating that there has
been no damage due to the laser exposure. The laser exposure used is the same applied for the
Raman measurements in this study, hence verifying non-destructive testing of the cells.
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Figure 3.3: To ensure that the trypan blue dye would function correctly in the event of cell
damage, the sample was washed with ethanol to kill the P4E6 cells and then more trypan blue
dye was added to test for cell damage. From this optical image, taken using a 63x dipping lens
with a numerical aperture of one, it was concluded that if the cell had been damaged by the
laser, then the trypan blue dye would have been uptaken by the cell therefore producing this
result.
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cancer, leukaemia and brain tumour cell spectra, respectively, prior to analysis. The 1447 cm−1 peak
is often used for normalisation in Raman cancer studies due to its small variance, making it ideal for
observing the relative variation in other peaks.
Figs. 3.6 and 3.7 show the same averaged spectra without normalisation together with the associated
standard error of the mean envelopes. The relatively small SE of the mean envelopes displayed in Figs.
3.6 and 3.7, especially in areas of the spectrum where there are prominent peaks, suggest that these
spectra are of a consistently high quality.
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Figure 3.4: Averaged Raman spectra taken in the fingerprint region (600–1800 cm−1) for
the direct patient derived primary cell cultures, H517–15 cancer (n=164), H517–15 normal
(n=161), H554–15 cancer (n=156), H554–15 normal (n=167), and the P4E6 cancer (n=149)
and PNT2–C2 normal (n=154) standard cell lines. The biological relevance of the key peak
assignments identified on the spectra are detailed in Table. 3.1. The six averaged spectra have
been linear baselined and normalised to the 1447 cm−1 peak, which represents the CH2 bending
mode of proteins and lipids. peak. The spectra are vertically shifted using an arbitrary offset
to aid visualisation.
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Figure 3.5: Averaged Raman spectra taken in the high wavenumber region (2700–3100 cm−1)
for the direct patient derived primary cell cultures, H517–15 cancer (n=164), H517–15 normal
(n=161), H554–15 cancer (n=156), H554–15 normal (n=167) and the P4E6 cancer (n=149)
and PNT2–C2 normal (n=154) standard cell lines. The biological relevance of the key peak
assignments identified on the spectra are detailed in Table. 3.1. The six average spectra have
been linear baselined and normalised to the 1447 cm−1 peak which represents the CH2 bending
mode of proteins and lipids. The spectra are vertically shifted using an arbitrary offset to aid
visualisation.
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Figure 3.6: Averaged Raman spectra in the fingerprint region (600–1800 cm−1) with asso-
ciated standard error envelopes for the direct patient derived primary cell cultures, H517–15
cancer (n=164), H517–15 normal (n=161), H554–15 cancer (n=156), H554–15 normal (n=167),
and the P4E6 cancer (n=149) and PNT2–C2 normal (n=154) standard cell lines. The six spec-
tra have been linear baselined and vertically shifted using an arbitrary offset to aid visualisation.
These spectra have not been normalised.
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Figure 3.7: Averaged Raman spectra in the high wavenumber region (2700–3100 cm−1)
with associated standard error envelopes for the direct patient derived primary cell cultures,
H517–15 cancer (n=164), H517–15 normal (n=161), H554–15 cancer (n=156), H554–15 normal
(n=167), and the P4E6 cancer (n=149) and PNT2–C2 normal (n=154) standard cell lines.
The six spectra have been linear baselined and vertically shifted using an arbitrary offset to
aid visualisation. These spectra have not been normalised.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.8: The convergence of the standard error of the mean as a function of the number
of spectra in the average, as indicated by the legend, for the fingerprint region only showing
the (a) H517–15 cancer (n=164), (b) H517–15 normal (n=161), (c) H554–15 cancer (n=156),
(d) H554–15 normal (n=167), (e) P4E6 cancer (n=149) and (f) PNT2–C2 normal (n=154) cell
lines.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.9: The convergence of the standard error of the mean as a function of the number
of spectra in the average, as indicated by the legend, for the high-wavenumber region only
showing the (a) H517–15 cancer (b) H517–15 normal (c) H554–15 cancer (d) H554–15 normal
(e) P4E6 cancer (f) PNT2–C2 normal cell lines.
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Figs. 3.8 and 3.9 show the convergence of the SE of the mean as a function of the number of
spectra in the average, for the fingerprint and high-wavenumber regions of each sample. The spectra
shown in these figures are plots of the standard error of the mean at each point on the spectrum, against
wavenumber, not raw spectra. The converged SE waves shown provide the error envelopes shown in Figs.
3.6 and 3.7. As more spectra are added to the average, the SE of the mean can be seen to be decreasing,
see figs. 3.8 and 3.9, up to the point where the data converges and the standard error is representative of
the whole data set. This convergence is important as it shows that the averaged spectra are statistically
representative of the whole population for each cell sample. Convergences showing almost identical
trends were also obtained for the standard deviations (not shown).
Another way to show statistical convergence is using peak intensity ratios (PIRs) and their associated
percentage standard errors. These types of convergence tests are especially important as PIRs will be
used to later assess the biomolecular information contained within the spectra. Figs. 3.10 and 3.11 show
the convergence of the percentage standard error of the mean for the peak intensity ratios I1447/I1653,
where 1447 cm−1 is the CH2 bending mode of proteins and lipids, and 1653 cm−1 is the C=C stretch of
proteins and lipids, and the I3008/I2850 PIR where 3008 cm−1 is the CH stretching of lipids and 2850
cm−1 is the CH2 stretching of lipids (see also Table. 3.1). These ratios were used to test for statistical
convergence as they have been previously used in the literature to differentiate normal cells from cancer
cells [27] [61]. These figures, together with the the convergence of the SE waves shown in Figs. 3.8
and 3.9, provide confidence in the statistical convergence of each data set, indicating that a sufficient
number of individual spectra were collected to faithfully represent the population average of each cell
line.
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PIR convergences allow a fit to be drawn so that the rate of convergence can be observed. A faster
convergence corresponds in this case to a more homogeneous sample population with respect to the PIR
studied, i.e. there is less variation amongst the cells. Greater homogeneity is to be expected for the
standard cell lines [72] [88]. Figs. 3.10 and 3.11 show that the sample which converged with the smallest
number of averaged spectra was the P4E6 cell line, with the PNT2–C2 cell line converging at a similar
rate to the primary patient samples. The faster convergence rate indicated that the P4E6 cell line has a
more homogeneous distribution of cell characteristics with respect to these PIR markerscompared to the
other cell lines studied. It was also expected that the PNT2–C2 cell line would be more homogeneous
than the primaries due to it being a standard cell line [72], although this was not the case for the
particular PIRs studied. These figures show a similar convergence rate to Figs. 3.8 and 3.9, as Figs. 3.8
and 3.9 show the standard error of the means, from which the convergences in Figs. 3.10 and 3.11 were
produced.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.10: The convergence of the percentage standard error of the mean, as a function
of the number of spectra in the spectral average for the PIR I1447/I1653 measured randomly
across the population of each cell line. The cell lines studied are (a) H517–15 cancer, (b)
H517–15 normal, (c) H554–15 cancer, (d) H554–15 normal, (e) P4E6 cancer and (f) PNT2–C2
normal.
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(a) (b)
(c) (d)
(e) (f)
Figure 3.11: The convergence of the percentage standard error of the mean as a function
of the number of spectra in the spectral average for the PIR I3008/I2850 measured randomly
across the population of each cell line. The cell lines studied are (a) H517–15 cancer, (b)
H517–15 normal, (c) H554–15 cancer, (d) H554–15 normal, (e) P4E6 cancer and (f) PNT2–C2
normal.
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The peak assignments that have been identified by peak fitting and shown in Figs. 3.4 and 3.5
are also consistent with the previously published literature on Raman spectroscopy studies of biological
samples [10] [11] [20] [27] (see also Table 3.1). All peaks positions obtained by fitting were averaged
across the six spectra, returning an uncertainty of approximately 1 cm−1 in the peak position, which is
also the same as the spectral uncertainty from the Raman instrument error.
Peak Position ± 1 (cm−1) Assignments
617 Proteins (CC twisting) [97]
641 Proteins (CC twisting) [97]
667 DNA/RNA [25]
713 Amino acids/methionine [10] [98]
724 DNA/RNA [99]
745 DNA/RNA [97]
757 Proteins, tryptophan (symmetric breathing) [66]
781 DNA/RNA [99]
827 DNA and proteins (proline, hydroxyproline, tyrosine) [100]
850 Proteins (single bond stretching of amino acids) [101]
875 Proteins and lipids (CC stretching) [102] [103]
894 Deoxyribose [104]
934 Proteins (CC, collagen) [102]
956 Cholesterol [66]
1000 Phenylalanine [105]
1008 Phenylalanine [106]
1029 Glycogen, collagen (OCH3, CC) [100] [107]
1062 DNA/RNA and lipids (CC stretch) [25]
1081
DNA/RNA, phospholipids (phosphate vibration) and lipids (CC
skeletal) [105] [100] [108]
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1096 DNA/RNA, and lipids [105] [109]
1125 Proteins (CN stretching) and lipids (CC skeletal) [97] [100]
1154 Proteins (glycogen) [107]
1172 Proteins (CH, tyrosine) [32]
1205 Proteins, collagen [107]
1232 Proteins (Amide III) [107]
1252 Guanine, cytosine (NH2) and lipids [104] [107]
1305 DNA/RNA, proteins (CH2, CH3) and lipids (CH2) [66] [102]
1336 DNA/RNA and proteins (CH2, CH3) [32]
1447 CH2 bending mode of proteins and lipids [110]
1480 Proteins (Amide ii) [110]
1549 Proteins (Tryptophan) [66]
1578 Guanine, adenine [25]
1600 Proteins (Amide I, C=O stretching, phenylalanine) [107]
1613 Proteins (Tyrosine, tryptophan C=C) [97]
1653 Proteins and lipid (C=C stretch) [66]
1679 Proteins (Amide I) [111]
2850 CH2 stretching of lipids [112]
2871 CH2 stretching and CH stretch of lipids and proteins [112]
2893
CH2 stretching of lipids and proteins, CH stretching of lipids and
proteins [112]
2937 Lipids (CH2, CH3) [112]
2970 lipids and cholesterol (CH3) [103]
3008 Lipids (unsaturated, CH stretching) [103]
3065 CH stretching of Lipids [113]
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Table 3.1: All peak positions identified in these experiments and their published assign-
ments along with examples of their uses in the literature. All peak assignments correspond to
Movasaghi et al. (2007). The peak positions in this study were identified by fitting and then
averaging across the 6 samples, this returned an associated error in the peak locations of 1
cm−1.
3.1.3 Principle Component Analysis (PCA) and Linear Discriminant Anal-
ysis (LDA)
Before any multivariate analyses were performed, every spectrum was first linear baselined and nor-
malised to the area under the curve using the Raman toolkit package [92] then scaled so that the mean
of each data point was zero, and the variance was one, using the statistical package, R v3.3.0.
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Figure 3.12: Results of PCA followed by LDA analysis for the direct patient derived primary
cell cultures, H517–15 cancer (n=164), H517–15 normal (n=161), H554–15 cancer (n=156),
H554–15 normal (n=167), and the P4E6 cancer (n=149) and PNT2–C2 normal (n=154) stan-
dard cell lines. Principle components one, two and three account for 43.4%, 19.6% and 4.9%
of the total variance, respectively.
Fig. 3.12 shows the results of principal component analysis (PCA) followed by linear discriminant
analysis (LDA) performed on the direct patient derived primary cell cultures, H517–15 cancer (n=164),
H517–15 normal (n=161), H554–15 cancer (n=156), H554–15 normal (n=167) and the P4E6 cancer
(n=149) and PNT2–C2 normal (n=154) standard cell lines. The LDA analysis was performed on the
first 80 principle components as per the Kaiser criterion, whereby only PCs with variance greater than
one in the standardised data are included [93]. Fig. 3.12 shows clear separation between most of the
samples with the exception of the two normal patient–derived primary cell culture samples (H517–15 and
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H554–15), which, as they are both samples from normal prostate tissue, are expected to be biologically
similar [11]. Fig. 3.12 also shows only a small separation between the H554–15 patient cancer sample
and the two normal primary culture cell samples. This lack of obvious separation indicates that the
H554–15 patient cancer sample is more spectrally, therefore biologically, similar to the normal samples.
Both standard cell lines (P4E6 cancer and PNT2–C2 normal) are also separate from the primary
cell culture samples (Fig. 3.12). This separation between direct patient derived normal cells and the
normal standard cell line (PNT2–C2) casts doubt on the use of standard cell lines in research and their
effectiveness in treatment development, as suggested in the literature [74] [75]. It has been suggested
that some standard cell lines do not provide accurate representations of patient biology due to differences
in the way immortalised cells react to hormones found in the body [114]. Capes–Davies et al. (2010)
suggested that as many as 29% of certain standard cell lines may be contaminated by a foreign cell
line or micro-organism [115]. Crow et al. (2003), using primary patient tissue samples, and Crow et
al. (2005), using standard cell line samples, came to different conclusions about the change in DNA
content between normal and cancer cells, using RS [11] [20]. It was reasonable to expect the P4E6
cancer cell line to be separate from the other cancer cell lines due to the difference in Gleason grade.
This separation affirms the ability of RS to distinguish not only cancer cells from normal cells, but also
its ability to separate cancers of different severity, as suggested by Crow et al. (2003) [11]. It should be
noted however that this separation could also be attributed to the P4E6 cell line being an immortalised
cell line, and not to differences due to malignancy.
The LDA process was verified using the leave-one-out cross validation method [11], whereby each
spectrum is left out of the initial LDA in turn then grouped by the linear discriminant functions. This
process returned an error of 14%, with the groupings shown in Table 3.2. A 0% error would show all the
spectra in their correct corresponding groups. Although an error of 14% is seemingly high, it is apparent
from the groupings that the majority of this uncertainty has arisen from the identification of the two
normal patient derived primary cell culture samples, which are expected to be biologically similar [11],
as well as the H554–15 cancer sample, which appears similar to the two normal samples.
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Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
H517–15
(cancer)
157 0 1 3 2 1
H517–15
(normal)
0 116 17 26 2 0
H554–15
(cancer)
0 18 128 9 1 0
H554–15
(normal)
0 30 10 123 4 0
P4E6
(cancer)
0 7 0 4 138 0
PNT2–C2
(normal)
0 0 0 0 0 154
Table 3.2: The results of the leave-one-out cross validation, performed on the LDA result
shown in Fig. 3.12. The total error in the LDA, calculated from the number of spectra that
were grouped incorrectly, is 0.14196 (14%). The H517–15 normal, H554–15 normal and H554–
15 cancer samples are spread across their relevant groups showing that the LDA was not able
to tell these spectra apart as well as the other samples.
The primary H554–15 cancer sample is not fully separated from its normal-match using PCA. Fig
3.13 shows the result of PCA using the first three principle components accounting for 55.7%, 6.8% and
4.7% of the total variance, respectively. Although the two samples are not fully separate there is a small
amount of separation in PC3. This result is corroborated by the PCA followed by LDA analysis shown
in Fig. 3.12, as well as the groupings for the leave-one-out cross validation of the LDA (Table 3.2).
Although Fig. 3.12 shows a small difference, there is little more separation between H554-15 cancer and
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normal than between the two primary normal samples. Table 3.2 is especially telling as the H554–15
cancer sample has spectra grouped in both the H554–15 and H517–15 normal groups. This result could
indicate that this sample is not in fact as high grade cancer (i.e. Gleason 7) as the first histopathology
informed. We are now consulting with the hospital, which provided these samples, to ascertain this. If
correct, this would then demonstrate Raman spectroscopy’s potential to discriminate not only cancer
cells from normal, as in much of the literature [95] but also to assess patient specific information, similar
to the study by Crow et al. (2003) [11] where samples were separated by Gleason grade using PCA.
The loadings for the principle components, which show the areas of greatest variance, for the primary
patient H554–15 cancer and normal cells (Fig. 3.14) show that what variance there is, primarily from
PC1, comes from peaks corresponding to DNA/RNA (745, 781 and 1578 cm−1), proteins (850 and
1125 cm−1), phenylalanine (1000 cm−1) and glycogen (934 and 1029 cm−1). However, large amounts
of the variance in PC1 can also be attributed to fluctuations in background between spectra, as shown
by regions of large negative variance between 450–700 cm−1 and large positive variance from around
1200–1700 cm−1. However as none of these principle components produce any separation between the
two samples using PCA (Fig. 3.13) this variance can only be attributed to variations across both groups
from the individual spectra in the entire H554–15 sample. LDA was not used here as in order to achieve
any separation, over 120 PCs had to be included, this violates the Kaiser criterion.
The cell lines P4E6 (cancer) and PNT2–C2 (normal) are separated using principle components one,
two and four accounting for 36.5, 13.3 and 5.4% of the total variance, respectively (Fig. 3.15). PC3
was replaced with PC4 in this case as no separation was seen using PCs one, two and three. From this
figure we can see that the two samples are separated only by PC4. PC1 and PC2, while representing
a greater share of the variance, only account for variance in the combined population of both samples,
and not differences between the two cell lines. LDA was not used here as separation was achieved using
only PCA.
Fig. 3.16 shows the corresponding loadings for the principle components in Fig. 3.15. The loading
for the principle component, which separates the P4E6 cancer and PNT2–C2 normal standard cell lines,
i.e. PC4, (Fig. 3.16) shows that the variance which separates the cancer from the normal sample
comes from peaks corresponding to DNA/RNA (724, 745 and 781), proteins and lipids (850, 1096, 1125,
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Figure 3.13: PCA results for the direct patient derived primary cell cultures, H554–15 cancer
(n=156), H554–15 normal (n=167) using the first three principle components, accounting for
55.7%, 6.8% and 4.7% of the total variance, respectively. No separation is seen here, indicating
that the two samples produce very similar spectra and any variance in the data cannot be
attributed to differences between the normal and cancer cells, only to the heterogeneity of the
population as a whole.
52
3.1 Raman Spectroscopy Studies of Prostate Cancer and Normal Prostate Cells
(a)
(b)
(c)
Figure 3.14: Loadings of the first three PCs for the H554–15 samples. These loadings suggest
that areas of high variance include 745 cm−1, 781 cm−1, 850 cm−1, 934 cm−1, 1000 cm−1, 1029
cm−1, 1125 cm−1 and 1578 cm−1 for PC1, 1000 cm−1 and 1653 cm−1 for PC2 and 781 cm−1,
827 cm−1, 850 cm−1, 1000 cm−1, 1029 cm−1, 1081 cm−1, 1125 cm−1, 1447 cm−1 and 1578
cm−1 for PC3. These markers however are not enough to discriminate between the 2 samples,
as shown in Fig. 3.13.
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Figure 3.15: PCA results for the P4E6 cancer (n=149) and PNT2–C2 normal (n=154) stan-
dard cell lines showing principle components one, two and four accounting for 36.5, 13.3 and
5.4% of the total variance, respectively. The separation seen here can be attributed entirely to
PC4, with PC1 and PC2 accounting only for the variance within the two samples combined.
PC3 was omitted here and PC4 included as PC3 contributed no separation between normal
and cancer.
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1205, 1600, 1613 and 1653 cm−1), phenylalanine (1000 cm−1) and glycogen (1029 cm−1). All of the
aforementioned peaks have been highlighted in the RS literature as possible markers for cancer, for
example, Crow et al. (2005) produced loadings with similar areas of high variance when using PCA
to separate normal prostate from prostate cancer samples [20]. The biomolecular assignments of these
peaks also correspond to biomarkers suggested in the literature as markers for cancer, for example
phenylalanine, as suggested by Huang et al. (2003) [32] and lipids, as suggested by Rysman et al.
(2010) [62] and Calvisi et al. (2011) [63].
PNT2–C2 (normal) is separated partly from the other, primary, normal samples most likely due to
the immortalisation process altering the biology of the cells. Fig. 3.17 shows this separation using the
first three principle components accounting for 50.6, 8.8 and 4.8% of the total variance, for PC1, PC2
and PC3, respectively, where the separation arises almost entirely from PC3. Similarly, Fig. 3.18, shows
that the P4E6 (cancer) sample is separate from the H517–15 cancer and slightly from the H554–15
cancer sample using principle components one, two and three, accounting for 43.1, 21.5 and 2.9% of the
total variance, respectively. The separation between the H517–15 cancer and the H554–15 and P4E6
cancer samples is attributed to PC2 and the small amount of separation between the H554–15 and P4E6
cancer samples can be attributed to PCs one and two. This separation is to be expected due to the
difference in gleason grade, however, the P4E6 and H554–15 cancer samples appearing to be similar
indicates that the H554–15 cancer may have more in common with the lower grade P4E6 cell line than
with the H517–15, Gleason seven, primary cell line.
The differences seen here between the primary samples and representative standard cell lines (specif-
ically for the normal samples) highlights one of the key aims of this research, to determine the accuracy
of RS when used on immortalised cell lines and to assess how closely these cell lines represent the
biology of actual patients. This is studied as previous work in other fields has cast doubt over the
reliability of standard cell lines with several reports in the literature of mis-identification and cross-
contamination [74] [75]. LDA was again not used here as increasing the separation shown in Figs. 3.17
and 3.18 required the inclusion of upwards of 100 PCs, in violation of Kaisers criterion.
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(a)
(b)
(c)
Figure 3.16: Loadings for principle components 1, 2 and 4 for the standard cell lines samples,
P4E6 and PNT2–C2. Only PC4 accounts for variation between the normal and cancer samples,
as shown in Fig. 3.15. The peaks which correspond to high variance in PC4 are 724 cm−1 745
cm−1, 781 cm−1, 850 cm−1, 1000 cm−1, 1029 cm−1, 1096 cm−1, 1125 cm−1, 1205 cm−1, 1600
cm−1, 1613 cm−1 and 1653 cm−1.
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Figure 3.17: PCA results for the direct patient derived primary cell cultures, H517–15 normal
(n=161), H554–15 normal (n=167) and the PNT2–C2 normal (n=154) standard cell line.
Figure 3.18: PCA results for the direct patient derived primary cell cultures, H517–15 cancer
(n=164), H554–15 cancer (n=156) and the P4E6 cancer (n=149) standard cell line.
The PCA results in Fig. 3.19 shows that the H517–15 cancer and normal samples are fully separated
using only the first three principle components, PC1, PC2 and PC3, accounting for 44.6, 23.1 and 4.1%
of the total variance, respectively. Fig. 3.20 shows the loadings for the principle components used to
separate the H517–15 cancer and normal samples with the first, second and third principle component
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results. Here, PC2 separates the normal from cancer cells as seen in Fig. 3.19
The only PC loading which separated the cancer and normal cells for the H517–15 sample was
PC2, as shown in Fig. 3.19. (Fig. 3.20) shows that the majority of the variance in PC2 comes from
peaks corresponding to amino acids (713 cm−1, DNA/RNA (745, 781 and 1578 cm−1), proteins and
lipids (1096 cm−1, 1125 cm−1, 1205 cm−1, 1600 cm−1, 1613 cm−1 and 1653 cm−1), Phenylalanine (1000
cm−1) and glycogen (934 and 1029 cm−1). These markers are corroborated in the literature by Crow
et al. (2005) [20] (DNA/RNA), Huang et al. (2003) [32] (phenylalanine), Rysman et al. (2010) [62]
(lipids) and Calvisi et al. (2011) [63] (lipids).
While the ability of RS to distinguish normal from cancer cells is not novel [11] [20] [27] the
PCA/LDA results here can also be used to inform a more targeted analysis using peak intensity ra-
tios [28]. By taking only the principle components which account for separation between normal and
cancer samples and singling out the loadings which show the greatest variance, the peak intensity ratio
biomarkers which correspond to malignancy can be identified. The loadings corresponding to the PCs
which separate the cancer cells from the normal cells, for each cell line, serve to confirm the results of
PIR analysis by showing the areas or individual peaks in the spectrum where there is variance between
the two groups. This should match the peak intensity ratios which also show a separation.
3.1.4 Peak Intensity Ratio (PIR) Comparisons
Peak intensity ratios (PIRs) allow for a relative comparison of individual peak intensities, which in turn
allows the biomolecular information associated with PIR changes to be extracted from the Raman spec-
tra. Some ratios, such as I1653/I1447, have been attributed in the literature to physical characteristics
of biological samples. This marker has been shown to differentiate cancer from treated cancer cells
previously by Potcoava et al. [27] who found a decrease in this ratio upon treatment for all cell lines.
In this case (I1653/I1447) is thought to represent the degree of mass unsaturation and the chain length
of lipids in a sample [26]. Lipid changes are well documented in cancer studies, making PIRs which
represent lipids an ideal candidate for discriminating cancer cell from normal [62] [63].
The mass unsaturation ratio (I1653/I1447), where 1447 cm−1 is the CH2 bending mode of proteins
and lipids and 1653 cm−1 is the C=C stretch of proteins and lipids can vary with both the degree of
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Figure 3.19: PCA results for the direct patient derived primary cell cultures, H517–15 cancer
(n=164), H517–15 normal (n=161) showing the first three principle components, accounting
for 44.6, 23.1 and 4.1% of the total variance, respectively. The separation seen here can be
attributed almost entirely to PC2, with a small contribution from 3. PC1 makes no contribution
to the separation, indicating that PC1 accounts only for the heterogeneity of the H517–15
population as a whole.
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(a)
(b)
(c)
Figure 3.20: Loadings of the first three principle components (PCs) for the H517–15 samples.
Only PC2 accounts for variation between the normal and cancer samples, as shown in Fig.
3.19. The peaks which correspond to high variance in PC2 are 713 cm−1, 745 cm−1, 781 cm−1,
934 cm−1, 1000 cm−1, 1029 cm−1, 1096 cm−1, 1125 cm−1, 1205 cm−1, 1578 cm−1 1600 cm−1,
1613 cm−1 and 1653 cm−1.
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mass unsaturation and the chain length of lipids in the sample [26]. Table 3.3 shows that this marker
was only able to fully discriminate (i.e. outside of the SE uncertainty) normal cells from cancer cells
for the H517–15 sample. For the H517–15 and standard cell line samples there is variance seen in PC2
and PC4, respectively, for 1653 cm−1 (Figs. 3.16 and 3.20), as these are the PCs which differentiate
the normal from the cancer cells for each of these samples (Figs. 3.15 and 3.19) it is expected that the
I1653/I1447 ratio may also provide some degree of separation. As the H554–15 sample shows very little
separation under PCA, it was expected that the PIRs would reflect this and show little to no separation,
as is the case here, shown in Table 3.3.
The results drawn from Table 3.3 are supported by the p-values from a T-test performed on the
data. The p-values are shown in Table 3.4.
It should be noted that the exact biomolecular interpretation of this ratio is questionable in terms
of being lipid specific, due to the peaks at 1447 cm−1 and 1653 cm−1 being convolved with other
biomolecules containing CH2 and double carbon bonds, such as amino acids [10].
I1653/I1447
(unsaturation
degree)
Standard
Error
I3008/I2850
(TUFA/TFA)
Standard
Error
H554–15 (normal) 1.98 (1.91–2.05) 0.07 0.35 (0.33–0.37) 0.02
H554–15 (cancer) 2.04 (1.97–2.11) 0.07 0.33 (0.31–0.35) 0.02
H517–15 (normal) 2.01 (1.94–2.07) 0.06 0.39 (0.37–0.41) 0.02
H517–15 (cancer) 2.5 (2.4–2.6) 0.1 0.24 (0.21–0.27) 0.03
PNT2–C2 (normal) 1.98 (1.89–2.07) 0.09 0.38 (0.36–0.40) 0.02
P4E6 (cancer) 2.07 (2.02–2.12) 0.05 0.29 (0.27–0.31) 0.02
Table 3.3: Table showing the mass unsaturation degree ratio (I1653/I1447) and TUFA/TFA
ratio (I2850/I3008) for all samples investigated.
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Cell type
P-value for I1653/I1447
(unsaturation degree)
P-value for I3008/I2850
(TUFA/TFA)
H554–15 0.5 0.5
H517–15 0.0001 0.0001
Standard cell lines 0.4 0.002
Table 3.4: Table showing the P-values obtained from a T-test when comparing the ratios
(I1653/I1447) and (I2850/I3008) between the normal and cancer samples for all cell types
investigated.
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Figs. 3.21–3.23 and Figs. 3.24–3.26 show the discriminatory peaks, informed by both PCA and PIR
analysis, against the 781 cm−1 (DNA/RNA) and 1447 cm−1 (lipids and proteins) peaks, respectively.
Markers which are not fully discriminated for one or more of the cancer/normal pairs are not shown on
these graphs. The peak at 1447 cm−1 was selected as a basis peak for the PIR analysis as it has been
used extensively to normalise Raman cell spectra in the literature [11] [96] [116]. 1447 cm−1 is used in
the literature to normalise as it often has a small variance, making it useful for studying the variance of
other peaks, which can be seen here in the PCA loadings (Figs. 3.14–3.20). Note that the 1447 cm−1
peak doe sappear in some of the loadings, but not those which correspond to differences between normal
and cancer cells. The peak at 781 cm−1 (DNA/RNA) [10] was used as it contributes one of the largest
variances between cancer and normal, as seen in the PCA loadings that separate these, i.e. PC4 for the
standard cell lines and PC2 for H517–15(Figs. 3.16 and 3.20). Crow et al. (2005), for example, found
large variances in the DNA/RNA peak at 781 cm−1 between prostate cancer samples at varying stages
of differentiation [20].
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Figure 3.21: PIR markers from the fingerprint peak intensity ratios against 781
cm−1(DNA/RNA) for the H517–15 primary patient samples. Markers shown here are fully
discriminatory for one or more of the cancer vs. normal pairs, non-discriminatory markers are
not shown.
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Figure 3.22: PIR markers from the fingerprint peak intensity ratios against 781
cm−1(DNA/RNA) for the H554–15 primary patient samples. Markers shown here are fully
discriminatory for one or more of the cancer vs. normal pairs, non-discriminatory markers are
not shown.
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Figure 3.23: PIR markers from the fingerprint peak intensity ratios against 781
cm−1(DNA/RNA) for the P4E6 cancer and PNT2–C2 normal cell line samples. Markers shown
here are fully discriminatory for one or more of the cancer vs. normal pairs, non-discriminatory
markers are not shown.
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Figure 3.24: Peak intensity ratio (PIR) markers from the fingerprint peak intensity ratios
against 1447 cm−1(lipids and proteins) for the H517–15 primary patient samples. Markers
shown here are fully discriminatory for one or more of the cancer vs. normal pairs, non-
discriminatory markers are not shown.
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Figure 3.25: PIR markers from the fingerprint peak intensity ratios against 1447 cm−1(lipids
and proteins) for the H554–15 primary patient samples. Markers shown here are fully discrim-
inatory for one or more of the cancer vs. normal pairs, non-discriminatory markers are not
shown.
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Figure 3.26: PIR markers from the fingerprint peak intensity ratios against 1447 cm−1(lipids
and proteins) for the P4E6 cancer and PNT2–C2 normal cell line samples. Markers shown here
are fully discriminatory for one or more of the cancer vs. normal pairs, non-discriminatory
markers are not shown.
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Phenylalanine has been linked to malignancy in prostate cells in RS studies using markers at 1000
cm−1 and 1600 cm−1. Increases in phenylalanine peaks for lung cancer were reported by Huang et al.
(2003) when the Raman spectra were normalised to the area under the curve [32]. The phenylalanine
peak at 1600 cm−1 forms part of a shoulder to the larger lipid/protein peak at 1653 cm−1 and is
therefore not an accurate representation of the phenylalanine content of the cells. The peak at 1000
cm−1, however, is not convolved and can be used as a reliable estimate of phenylalanine content [10].
From the PCA loadings shown in Figs. 3.14, 3.14 and 3.20 we see that the peak at 1000 cm−1 is one of
the largest sources of variance between the samples, specifically for loadings which account for separation
between the normal and cancer samples, i.e. PC4 for the standard cell lines and PC2 for H517–15. Figs.
3.21 – 3.23 and Figs. 3.24 – 3.26 show the 1000 cm−1 phenylalanine peak against the 781 cm−1 and
1447 cm−1 peaks respectively. From these figures we see that the PIR for phenylalanine is increased
relative to both the 781 cm−1 and 1447 cm−1 peaks for the H517–15 patient cancer sample, relative to
its normal match. However, both the H554–15 patient and standard cell lines show no change in this
PIR marker for cancer vs. normal.
The Raman peaks corresponding to DNA/RNA which are less convolved and therefore more rep-
resentative of the DNA/RNA content of the cell are at 745 cm−1 and 781 cm−1 [10]. From the PCA
loadings shown in Figs. 3.14, 3.14 and 3.20 we see that there is a large amount of variance between
cancer and normal for the 745 cm−1 and 781 cm−1 DNA/RNA peaks in the H517–15 and standard cell
line samples.
Fig. 3.24 shows the PIR at 781 cm−1 (DNA) to be decreased for H517–15 (cancer) relative to the
1447 cm−1 peak, whereas Figs. 3.25 and 3.26 show no discriminatory change in the I781/I1447 PIR
for both H554–15 and the standard cell lines comparisons. The general increase seen in most PIRs
when taken against the 781 cm−1 peak (Fig. 3.21) in the H517–15 comparison also suggests amarked
sensitivity to the 781 cm−1 peak.
Figs. 3.21 and 3.24 show that two of the biggest discriminatory markers between the H517–15
cancer and normal samples occurs for the I1578/I781 and I1578/I1447 peak intensity ratios, with 1578
cm−1 corresponding to guanine and adenine [10], which are both components of DNA [117]. From the
PCA loadings shown in Fig. 3.20 we see a high degree of variance in this peak in PC2 for the H517–15
70
3.1 Raman Spectroscopy Studies of Prostate Cancer and Normal Prostate Cells
sample suggesting it is a marker for cancer. This peak also appears in PC1 and PC3 for the H554–15
sample and PC3 for the standard cell line samples. These loadings, however, do not correspond to any
difference between the normal and cancer cell spectra. The 1578 cm−1 PIR is increased relative to the
1447 cm−1 protein/lipid peak for cancer compared to its normal match in the H517–15 sample. This
result can be compared to the other samples studied which did not show any relative difference for this
marker between cancer and normal (Figs. 3.25 and 3.26).
There is some debate in the literature as to whether up-regulation or down regulation of DNA Raman
markers is indicative of cell malignancy. Crow et al. 2003 suggested that malignancy can be represented
in Raman spectra by higher intensities in peaks corresponding to DNA/RNA [11] when normalised to
the 1447 cm−1 peak, which is agreement with Taleb et al [67]. However, in 2005, Crow et al. concluded
that the poorly differentiated, or more aggressive prostate cancer cell line, DU145 had lower levels of
nuclear materials and some proteins when compared the more well differentiated cell lines [20]. This
lack of agreement raises the question as to whether DNA markers can be used to accurately discriminate
between cancer and normal cells in the prostate using RS.
It is widely known that DNA is not uniformly distributed within the nucleus of the cell and that
prostate cancer cells do express more DNA than non-cancerous cells [118]. This non-homogeneous
distribution of DNA may lead to inaccuracies in spectra taken from points within a nucleus. This may
have been a factor in previous literature therefore leading to this discrepancy. In this work, steps were
taken to ensure that the Raman spectra collected were statistically and robustly representative of the
average nucleus of each sample. For example, Figs. 3.8 and 3.9 show clearly that the standard error of the
mean converged for all samples in both the fingerprint and high–wavenumber regions. The high number
of spectra and good convergence obtained in our study indicate a good level of confidence that these
results are indicative of the DNA/RNA content of the nucleus of the samples studied. Our conclusion
from this therefore, is that markers relative to DNA/RNA are discriminatory in prostate cancer vs.
normal cell line studies for both the H517–15 primary patient derived sample and the PNT2–C2 normal
and P4E6 cancer standard cell lines.
The peak at 850 cm−1 (proteins) [10] appears in PC4 for the standard cell line PCA. The 850 cm−1
peak provides a small discrimination between normal and cancer for the P4E6 cancer and PNT2–C2
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normal standard cell lines (Fig. 3.26) when taken against the peak at 1447 cm−1.
The PIR H554–15 patient results in Figs. 3.22 and 3.25 show that, despite there being similarities
between cancer vs. normal in most of the PIRs, and the PCA loadings (Fig. 3.13), there are still two
large differences between the cancer and normal spectra. These differences in PIRs are apparent at 1252
cm−1 and 1305 cm−1 relative to both 781 cm−1 and 1447 cm−1. The 1252 cm−1 and 1305 cm−1 peaks
are heavily convolved with DNA, lipids and proteins [10]. These markers were not picked up by the
PCA.
Other peaks are present in the Raman spectrum for the standard cell lines do provide discrimination
between cancer and normal, yet were not picked up by the PCA loadings. This is possibly due to being
convolved with other peaks which account for greater variances across the sample as a whole. These
peaks are 956 cm−1 (cholesterol), which is down-regulated in cancer relative to 1447 cm−1 and 1096
cm−1 (DNA/RNA, proteins and lipids), which is down regulated in cancer relative to 1447 cm−1 (Fig.
3.26). Also fully separated are PIR markers for various protein peaks at 1205 cm−1 and 1600 cm−1
which are both up-regulated relative to 1447cm−1 and 1480 cm−1 which is down-regulated relative to
1447 cm−1 (Fig. 3.26).
With the exception of the cholesterol peak at 956 cm−1 it is very difficult to extract any biomolecular
information from these markers due to their high degree of convolution with other markers hence lack
of distinct biological assignment (Table. 3.1). Many of these peaks were highlighted as discriminatory
between different prostate cancer cell lines at various stages of differentiation, by Crow et al. 2005.
PCA loadings in Crow et al. (2005), show variances between different stage cancers at 956 cm−1, 1090
cm−1 and 1480 cm−1 in agreement with this study. The peak at 1205 cm−1 appears in the loadings in
Crow et al. as a shoulder to a larger peak around 1190 cm−1, it is difficult to ascertain whether this
corresponds to any variance specific to 1205 cm−1.
Fig. 3.24 shows further discriminatory markers between cancer vs normal cells for the H517–15
patient sample at both 1480 cm−1 (down-regulated in cancer) and 1600 cm−1 (up-regulated in cancer)
both of which correspond to proteins and show similar results for the standard cell lines (Fig. 3.26).
The 1600 cm−1 peak was picked up by PC2 for the H517–15 sample, however 1480 cm−1 was not (Fig.
3.20).
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This lack of agreement between some of the PCA and PIR analysis results highlights a key flaw in
PCA. Despite careful pre-processing to remove the background and normalise each individual spectra
it is clear from PC1 for each sample that variances in background are still present (Figs. 3.14, 3.16
and 3.20). It was concluded that this lack of agreement between these two techniques stems from these
difficulties. The accuracy of the PIR analysis in this study is corroborated by the convergences shown
in Figs. 3.8 and 3.9 and the good agreement in the cancer biomarkers between the H517–15 primary
patient sample, and the non-RS literature.
The loadings from the PCA show a large degree of variance in PC1, PC2 and PC3 for the H517–15
sample in the region between 1029 cm−1 and 1100 cm−1, Fig. 3.24 shows that the peaks at 1029, 1062,
1081 and 1096 cm−1 are all up-regulated in the cancer sample relative to 1447 cm−1. The peaks in this
region all correspond to a variety of proteins, lipids, phospholipids and DNA/RNA [10] all convolved
with one another, again making it difficult to extract any meaningful biomolecular information, however,
showing there to be global biomolecular differences between the cancer vs normal samples for this patient.
Also discriminatory is the ratio I1252/I1447, where 1252 cm−1 corresponds to guanine and lipids, which
is down-regulated in cancer. Several of these markers were shown to discriminate between cancer vs
normal cells by Crow et al. (2005) in the PCA loadings [20], specifically the region between 1029 cm−1
and 1100 cm−1 and the 1252 cm−1 peak.
One of the drawbacks of RS studies on complex biological systems, such as cells, is that there can be
large, extensive convolution of different biomolecular signals, such as the 1029-1100 cm−1 region. While
regions such as this can provide global markers for separating cancer cells from normal cells, as with the
H517–15 and standard cell line samples in this study (Figs. 3.24 and 3.26) it is difficult to determine
the biomolecular meaning behind these markers, also conferred by Notingher et al. 2004 [25].
The TUFA/TFA (total unsaturated fatty acids/total fatty acids) ratio (I3008/I2850) is directly
proportional to the unsaturated fatty acid component of a cells membrane composition [27] [26] [61]. A
lower TUFA/TFA ratio, or unsaturation degree, is indicative of de novo lipogenesis, the conversion of
excess carbohydrates into fatty acids, which is thought to be a hallmark of malignancy in cells [62] [63].
Although no PCA/LDA was performed on the high–wavenumber region for this study, the TUFA/TFA
marker is known in the RS literature as a marker for malignancy in cells.
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For the H554–15 cancer and normal matched samples it was not possible to fully differentiate (i.e.
outside of the SE uncertainty) between the normal and cancer cells using the TUFA/TFA marker, as
shown in table. 3.3. This is because the values for the TUFA/TFA ratio for both normal and cancer
fall within the SE range of the other (Table. 3.3). A similar finding was reported by Neiva et.al, who
compared malignant and normal breast cancer cells [61] and found that the TUFA/TFA marker was
not sensitive enough to fully differentiate the samples. However, the H517–15 patient samples and the
standard cell lines (cancer vs normal) saw a decrease in this ratio for the cancer cells outside of the SE
range of the normal cells (Table. 3.3). Neiva et al. predicted that cell malignancy would correspond
to a decrease in this ratio due to an increase in the total number of lipids (TFA) [56], but could not
acquire sensitive enough data to prove this hypothesis [61].
A previous RS study by Potcoava et al. found that the TUFA/TFA ratio can be used to discriminate
hormone responsive prostate cancer cell lines, such as LNCaP [71], before and after treatment with
medroxyprogesterone acetate, a hormone cancer treatment [27]. In this study the TUFA/TFA ratio
separates both the P4E6 cancer cell line sample and H517–15 primary patient cancer sample from all
three normal samples, which group together with a higher value (Table. 3.3). Also grouped with the
three normal samples is the H554–15 cancer sample which serves to re-affirm the PCA/LDA findings,
where the H554–15 cancer sample behaves more like normal prostate cells.
Figs. 3.27 – 3.29 show the averaged, baselined and normalised spectra, laid over one another for
direct comparison. The spectra in these figures are normalised against 1447 cm−1. These figures allow
a direct comparison of the peak heights relative to the 1447 cm−1 peak. From these figures we can
confirm the findings of the PIR analysis by inspecting the differences in intensity between particular
peaks. This, however, is a far less quantitative measure of the relative intensities and should be used
only as a visual aid.
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Figure 3.27: Raman spectra for the H554–15 primary patient samples. The spectra have been
averaged, baselined and normalised against 1447 cm−1. The spectra have not been shifted so
a direct comparison can be made.
Figure 3.28: Raman spectra for the P4E6 cancer and PNT2–C2 normal cell lines. The spectra
have been averaged, baselined and normalised against 1447 cm−1. The spectra have not been
shifted so a direct comparison can be made.
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Figure 3.29: Raman spectra for the H517–15 primary patient samples. The spectra have been
averaged, baselined and normalised against 1447 cm−1. The spectra have not been shifted so
a direct comparison can be made.
3.1.5 Prostate Cancer Summary
This work demonstrates the ability of RS to not only differentiate different standard cell lines, but
also differentiate normal cells from cancer cells for a primary patient derived sample. For the primary
patient sample, H517–15 RS was able to identify several biomarkers which are consistent with biological
literature on cancer, such as the down regulation of the TUFA/TFA ratio in cancer, indicating de
novo lipogenesis, a hallmark of cancer [62] [63]. Other markers include the increase in the 1000 cm−1
phenylalanine peak in cancer relative to the 1447 cm−1 peak, in agreement with Huang et al. (2003) [32]
and the increase in the guanine and adenine peak at 1578 cm−1 in cancer, relative to the 1447 cm−1
peak, in agreement with Crow et al. (2003) [11].
These PIRs are, for the most part, also corroborated by PCA loadings which separate the normal
cells from cancer cells. However, some of the discriminatory PIR markers are not present in the relevant
PCs. Despite careful pre-processing it is apparent, especially so in the first PCs, that the spectral
background contributed a large portion of the variance. This may have caused certain discriminatory
peaks to become lost in the large background variance.
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This study also highlighted the need for more work to be done using primary patient derived sam-
ples as opposed to standard cell lines. This outcome is made apparent throughout this chapter by
the disagreements in the biomarkers between the H517–15 primary samples and P4E6 and PNT2–C2
standard cell line samples. The biomolecular information presented in the H517–15 data, as previously
stated, closely matches what is known about prostate and other cancers, whereas there is considerable
disagreement with the standard cell lines. This could lead to the development of treatments or diag-
nostic techniques which, while functional in a laboratory using cell lines, have little relevance to actual
patient cancers.
This study found that a second primary patient derived sample, H554–15, displayed little difference
between its cancer and normal matched spectra, despite having similar first histopathology. This result
could serve to highlight the ability of RS to replace tissue histopathology as a diagnosis technique. The
H554–15 sample has been sent back to the source hospital for further testing to ascertain the accuracy
of the RS result.
3.1.6 Further Work For Raman Spectroscopy Studies of Prostate Cancer
To expand on the work in this study it would be useful to complete principle component analysis on the
high wavenumber (2700–3100 cm−1) region of the prostate cancer spectra. The graphs and PC loadings
from this could inform a deeper lipidomic PIR analysis.
Also, future work could involve adding further primary patient samples and standard cell lines
to this data set in order to understand fully where the inconsistencies lie between cancer vs. normal
samples. As has been set out in this study and other studies in the literature [74] [75], standard cell lines
which are currently used to represent patient biology for both cancer and normal prostate cells do not
exhibit the matching Raman spectra which would be expected. Especially in the case of the PNT2–C2
normal prostate cell line, the biomolecular signatures in its Raman spectra are stark in contrast to those
of the normal primary patient samples. This is something which must be addressed. Finally, adding
further primary cancer samples and a Gleason seven standard cell line, would provide the opportunity
to determine the ability of RS to provide patient specific biomolecular information pertaining to things
such as Gleason grade, similar to work by Crow et al. (2003), using PIR analysis. Adding a standard cell
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line which is thought to more closely represent the biology of the primary patient samples in this study
would allow for a more direct comparison of the use of standard cell lines in prostate cancer research.
Aside from biomolecular analysis, Raman spectroscopy has proved that when combined with a
multivariate analysis technique, such as PCA/LDA, it can achieve very low errors when diagnosing
cancer from normal cells. The application of this in practice, in a hospital could drastically reduce both
cost and error rates. Additionally, although great care was taken in the pre-processing of the spectra
prior to PCA/LDA in this work, it is possible that manual baseline subtraction could improve the quality
of the loadings. Better quality loadings would allow peaks which are currently lost in background to
be identified. It was not possible for this thesis to perform manual background subtraction as it would
have required the manual processing of over 1000 individual spectra.
3.2 Raman Spectroscopy Studies of Streptomyces coelicolor
Bacteria
This section of the study was performed as part of a contribution to a paper entitled “Antibiotic
hypersensitive mutants of S. coelicolor”, which aims to probe the underlying mechanisms behind a
mutation in S. coelicolor bacteria which causes a loss of intrinsic antibiotic resistance [1]. It was proposed
that Raman spectroscopy be used to analyses bulk S. coelicolor cultures to determine changes in lipid
content between three different strains. The three different strains to be analysed are J1929, the ‘wild’
type with no mutations or treatments, DT3017, the strain with the mutation causing loss of antibiotic
resistance and PDT16, the treated, mutated strain. The treatment is designed to reverse the effects
of the mutation in PDT16 and return the bacteria to a state similar to that of the J1929 sample by
supplementing the mutated ppm1 gene in the DT3017 with ppm1 encoding plasimids [1].
This study was able to identify changes in lipid content between the J1929 and DT3017 samples, as
expected. This study was also able to show a return to the wild type lipid composition for the PDT16
treated sample, indicating that the treatment was effective.
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Figure 3.30: An optical image, using a 100x objective microscope lens with a numerical
aperture of 0.9, of the surface of the S. coelicolor sample J1929. Owing to the rough surface of
the sample and the confocal nature of the microscope, the in focus area is very small, shown
in the red box.
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3.2.1 Raman Spectra of Streptomyces coelicolor Bacteria
This study was performed as part of a collaboration on a paper in preparation with Prof. Maggie Smith’s
group at the University of York to look at the causes and effects of a mutation in the ppm1 gene of S.
coelicolor bacteria and its subsequent treatment. The three samples used in this study are J1929, the
‘wild’ type S. coelicolor with no mutations or treatments, DT3017, the strain with the mutation in the
ppm1 gene, and PDT16, the mutant strain which has been treated.
Differential RNA expression analysis performed by Prof. Smith’s group found that the mutant strain
displayed a switch from catabolism (the breaking down of molecules), to anabolism (the building of more
complex molecules) [119]. This dramatic switch has led to a change in membrane composition within
the cells, in turn altering the lipid content. This is thought to be causing the loss of intrinsic antibiotic
resistance seen in the ppm1 mutant [1]. Further to this, DESeq analysis of RNA sequencing data on the
three strains showed that of the 658 genes altered between the J1929 and DT3017 strains, 574 of these
changes showed some restoration toward J1929 in the PDT16 strain [1]. These results together suggest
that the J1929 wild type and DT3017 treated types should have similar lipid compositions, different to
the PDT16, mutant type.
Raman was used to assess the lipid content of three samples by means of the TUFA/TFA (Total
Unsaturated Fatty Acid/Total Fatty Acid) ratio (I3008/I2850) [27] [26]. Both Potcoava et al. and Nieva
et al. used this ratio and the mass unsaturation ratio (I1662/I1446) (C=C/CH2) band to determine
changes in the lipid content of human cancer cells [27] [61]. Potcoava et al. also used the I1662/I1294
ratio, which is also related to the unsaturated content of lipids [27]. Wu et al. performed RS lipidomics
on single algae cells using the I1662/I1446 PIR. They showed that the peak intensity ratio (I1662/I1447)
correlates to the degree of lipid unsaturation in extracted lipids from algae cells. Wu et al. however
identified the 1446 cm−1 and 1662 cm−1 peaks as being related to lipids only, which in the case of
Raman on pure lipids holds true [26]. In this study, the 1446 cm−1 and 1662 cm−1 peaks are identified
as being convolved with proteins, making them unsuitable for performing lipidomics (see Table. 3.5).
The TUFA/TFA (I3008/I2850) ratio was used in this study as it relates only to pure lipid peaks [10].
Very little quantitiative high wavenumber (2750–3110 cm−1) Raman analysis has been published on
bacteria, meaning the use of the TUFA/TFA ratio on S. coelicolor bacteria in this study is novel.
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The use of the TUFA/TFA ratio is, however, justified by the similarities in spectral profile between S.
coelicolor and other cell samples which have used the TUFA/TFA ratio [27] [61].
The averaged S. coelicolor Raman spectra for the three strains, J1929 (wild), PDT16 (treated) and
DT3017 (untreated), (Figs. 3.31 and 3.32) and the peak position assignments in Table. 3.5 are consistent
with previous RS literature on Streptomyces cells [80] and other published RS works on bacteria [84]. An
example of previously published Raman spectra on Streptomyces bacteria can be seen in Fig. 1.4 [80],
showing favourable comparison with the spectra in Figs. 3.31 and 3.32. All peak positions identified
in Figs. 3.31 and 3.32 were obtained by fitting the average spectra for each sample, then averaging
the peak positions, the peak positions and their assignment are shown in Table. 3.5. The associated
uncertainty in the peak positions is 1cm−1, which is the same as the uncertainty due to the error in the
Raman equipment.
The convergence of the percentage SE of the TUFA/TFA peak intensity ratio (I3008/I2850) [27] as
a function of the number of randomly selected individual spectra in the average indicates that sufficient
spectra were collected from each strain to establish reliable statistics for the measurements (Figs. 3.33,
3.34 and 3.35). The convergence plots shown in Figs. 3.33, 3.34 and 3.35 give insight into the hetero-
geneity of the samples under analysis. As these are bulk samples (i.e. not sampled at the single cell
level), as opposed to the single cell sampleing used in the prostate cancer study, there is likely to be a
greater variation in the spectra [80]. All of the percentage SE of the TUFA/TFA peak intensity ratios
converge at roughly the same rate for this study, indicating a uniform heterogeneity across the three
samples.
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Figure 3.31: Averaged Raman spectra in the fingerprint region (600-1800 cm−1)) for the
three S. coelicolor cell lines (J1929 wild-type, PDT16 treated and DT3017 untreated) showing
the key peak assignments (Table 3.5). The spectra are vertically shifted using an arbitrary
offset to aid visualisation.
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Figure 3.32: Averaged Raman spectra in the high-wavenumber region (2750-3110cm−1) for
the three S. coelicolor cell lines (J1929 wild- type, PDT16 treated and DT3017 untreated)
showing the key peak assignments (Table 3.5). The spectra are vertically shifted using an
arbitrary offset to aid visualisation.
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Peak Position ± 1(cm−1) Assignments
746 DNA/RNA [97]
782 DNA/RNA [99]
1000 Phenylalanine [105]
1096 DNA/RNA, and lipids [105] [109]
1446 CH2 bending mode of proteins and lipids [110]
1460 Lipids (CH2/CH3) [100]
1480 Proteins (Amide II) [110]
1578 Guanine, adenine [25]
1662 Proteins and lipid (C=C stretch) [66]
2850 CH2 stretching of lipids [112]
2871 CH2 stretching and CH stretch of lipids and proteins [112]
2900
CH2 stretching of lipids and proteins, CH stretching of lipids and
proteins [112]
2934 Lipids (CH2, CH3) [112]
2970 lipids and cholesterol (CH3) [103]
3008 Lipids (unsaturated, CH stretch) [103]
Table 3.5: All peak positions identified in these experiments and their published assign-
ments along with examples of their uses in the literature. All peak assignments correspond to
Movasaghi et al. (2007). These peak positions were identified by fitting the average spectra
for each sample, then averaging the peak positions. The associated error in the peak locations
is approximately 1cm−1.
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Figure 3.33: Convergence of the percentage standard error of the mean (SE) for the
TUFA/TFA peak intensity ratio I3008/I2850 for the J1929 (wild) cell line as a function of
the number of randomly chosen spectra comprising the spectral average. In total, 42 individ-
ual spectra were averaged.
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Figure 3.34: Convergence of the percentage standard error of the mean (SE) for the
TUFA/TFA peak intensity ratio I3008/I2850 for the PDT16 (treated) cell line as a function of
the number of randomly chosen spectra comprising the spectral average. In total, 55 individual
spectra were averaged.
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Figure 3.35: Convergence of the percentage standard error of the mean (SE) for the
TUFA/TFA peak intensity ratio I3008/I2850 for the DT3017 (untreated) cell line as a func-
tion of the number of randomly chosen spectra comprising the spectral average. In total, 40
individual spectra were averaged.
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3.2.2 Peak Intensity Ratio Comparisons
The TUFA/TFA marker shows that the treated PDT16 cells regain a similar lipid composition to that of
the J1929 wild cells when comparing the TUFA/TFA marker mean values and the TUFA/TFA marker
ranges that take into account the SE (Table 3.6). The TUFA/TFA marker for the DT3017 untreated
cells lies outside of the range obtained for the J1929 wild and PDT16 cell lines confirming that it has a
different lipid composition, specifically, a larger unsaturated fatty acid component.
S. coelicolor cell line
No. of spectra per
spectral average
TUFA/TFA ratio
± SE
TUFA/TFA
range
J1929 (wild) 42 0.47 ± 0.05 0.42 - 0.52
PDT16 (treated) 55 0.51 ± 0.03 0.48 - 0.54
DT3017 (untreated) 40 0.60 ± 0.04 0.56 - 0.64
Table 3.6: Table showing the number of spectra and TUFA/TFA ratios with associated errors
for all samples
S. coelicolor cell line comparison
P-value for TUFA/TFA
ratio
J1929 (wild) vs. PDT16 (treated) 0.47
J1929 (wild) vs. DT3017 (untreated) 0.047
DT3017 (untreated) vs. PDT16 (treated) 0.049
Table 3.7: Table showing the P-values obtained from a T-test when comparing the
TUFA/TFA ratio between the three different samples.
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This result concurs with the findings of the differential RNA expression analysis whereby the mutant
strain displayed a switch from catabolism (the breaking down of molecules), to anabolism (the building
of more complex molecules) [1] [119]. This change led to a change in membrane composition within
the cells, as corroborated by the TUFA/TFA PIRs (Table. 3.6). Further to this, the result shows a
return to the wild type lipid composition after treatment, suggesting a restoration of the ppm1 gene.
This result is corroborated by DESeq analysis of the RNA sequencing data, whereby of the 658 genes
altered between J1929 and DT3017, 574 of these changes showed some restoration toward J1929 in the
PDT16 strain [1]. This agreement between RS and other established bioanalysis techniques re-affirms
the technique and specifically the use of the TUFA/TFA ratio as an indication of lipid content in this
study, thus indicating a broad range in its application in biological samples. These results are supported
by the t-test results displayed in table 3.7. These p-values support the differences, or lack thereof,
between the three samples discussed.
3.2.3 Further work for Raman Spectroscopy Studies of Streptomyces coeli-
color Bacteria
This study consisted of only a small fraction of the analysis which RS is capable of for this type of
sample. This was a side project to the main prostate cancer study which aimed to firstly provide data
to a wider study by Prof. Maggie Smith’s group at the University of York and to highlight the versatility
of RS as a biomolecular analysis technique. Further work with these samples would be to complete both
a full principle component analysis and peak intensity ratio analysis in both the high–wavenumber and
fingerprint regions, similar to that carried out for the prostate cancer study. The same considerations
that are being made for further work on the prostate cancer samples must also be made here with
regards to the pre-processing of individual spectra, prior to PCA/LDA.
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Conclusions
This work demonstrates the ability of Raman spectroscopy (RS) to probe information relating to
biomolecular changes between a range of samples, specifically, standard and primary prostate and
prostate cancer cell lines, and bulk S. coelicolor bacteria.
Using principle component analysis and linear discriminant analysis (PCA/LDA) this study was able
to identify differences between spectra taken from primary patient derived prostate and prostate cancer
cell lines (H554–15 and H517–15). PCA determined that the H554–15 cancer and normal samples had
similar spectra, therefore were biologically similar, but not identical. The H517–15 cancer and normal
samples were fully separated using PCA. Examination of the loadings for the principle components (PCs)
which separate the cancer cells from the normal cells allows the peaks, or groups of peaks, which vary
between the two to be pin-pointed. As no PC separated the H554–5 sample, the loadings for the PCs
showed only the variance between individual spectra across both the normal and cancer cells combined.
The PC responsible for separating the H517–15 cancer and normal cell spectra (PC2) held information
on which peaks varied between the two. The peaks identified in PC2 were the peaks corresponding
to amino DNA/RNA (745, 781 and 1578cm−1), proteins and lipids (1096cm−1, 1125cm−1, 1205cm−1,
1600cm−1, 1613cm−1 and 1653cm−1), Phenylalanine (1000cm−1) and glycogen (934 and 1029cm−1),
these findings were corroborated in the literature.
PCA was also able to separate the two standard cell lines (P4E6 cancer and PNT2–C2 normal).
The loading for the PC which provided this separation (PC4) highlighted the points of variance between
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the two samples to be the peaks corresponding to DNA/RNA (724, 745 and 781), proteins and lipids
(850, 1096, 1125, 1205, 1600, 1613 and 1653cm−1), phenylalanine (1000cm−1) and glycogen (1029cm−1).
Once again, variances between normal and cancer cells at these peaks was corroborated in the literature.
PCA also found separations between all three of the cancer cell samples. Given that the H554–15
sample showed very little separation between cancer and normal, and the P4E6 cancer and H517–15
cancer are of different Gleason grade, it is expected that the three samples would show differences.
PCA also found that for the three normal samples, the two primary normal samples clustered together,
this was expected as they have similar biologies, both being patient derived normal prostate tissue.
Also expected was the PNT2–C2 (normal) sample to cluster with the primary normal samples. This
was expected as the PNT2–C2 sample is supposed to be representative of normal prostate cells. This,
however, was not the case, indicating that something in the processing of the PNT2–C2 cells from
patient sample to immortalised standard cell line has altered the biology in such a way as to make them
un-representative of patient biology. Further to this study it would be of use to add a Gleason 7 prostate
cancer cell line to this data, to determine if similar changes occur for all cell lines. To bolster this data
it would also be useful to add further primary patient samples with confirmed histopathology.
PCA has become a staple in RS literature. It does, however, have drawbacks. PCA requires a large
amount of pre-processing in order to be able to isolate differences between the samples that are not
related to background or spectral noise. This pre-processing, for studies such as this, which involved
over 1000 individual spectra, each with subtly different noise and background characteristics, can be
time and resource consuming.
The peak location highlighted in the PC loadings were used to inform targeted peak intensity ratio
(PIR) analysis. As expected, PIR analysis found very little difference between the H554–15 cancer and
normal cells. Only small differences are present in the PIR analysis of the H554-15 samples, in agreement
with the PCA/LDA results for the sample. For the H517–15 samples the following PIR changes were
noted: an increase in the 713cm−1 amino acid/methionine peak in cancer relative to 1447cm−1, an
increase in the 1000cm−1 phenylalanine peak in cancer relative to the 1447cm−1 peak, an increase in
the guanine and adenine peak at 1578cm−1 in cancer, relative to the 1447cm−1 peak, and a decrease in
the TUFA/TFA (I2850/I3008)ratio in cancer, amongst others. These biomarkers are all in agreement
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with various sources in the literature, both RS and otherwise, affirming the use of Raman to probe
accurate biomolecular information from live cell samples. Further to this study it would be useful to
expand the PIR analysis to include the whole of the high–wavenumber region of the spectra. In future
studies the addition of further primary patient samples would allow a comparison of PIRs, RS has
proven here that the technique is sensitive enough to distinguish between different cancers. The next
step would be to study large volumes of patient samples to build a reliable, multi-patient diagnosis
method, likely involving a combination of PCA and PIR analysis.
The primary limitation of PIR analysis is the amount of information contained within a single
spectra. While techniques such as PCA can provide regions of high variance within the spectra, a
technique such as PIR is needed to extract meaningful biomolecular data. For a system as complex as
a living cell, a large number of peaks are convolved with other peaks, making the process of extracting
biomolecular data from them difficult. With developments in optical technologies increasing spectral
intensity and reducing uncertainty in the measurements, and increased access to primary patient samples
for research purposes it is possible for Raman to become a standard in cancer diagnosis, reinforcing or
replacing the flawed current techniques.
The picture with the standard cell lines (P4E6 cancer and PNT2–C2 normal) is not as clear. While
the samples show some biomolecular markers in agreement with the literature, such as a decrease in the
TUFA/TFA ratio for cancer, other markers, such as phenylalanine (1000−1) and guanine and adenine
(1578cm−1) show disagreement with both the H517–15 results and the wider literature on prostate and
other cancers. This result further calls into question the use of standard cell lines in cancer research and
indicates a move toward using primary patient derived cell lines exclusively else risking the development
of ineffective technologies.
The second part of this study on the use of RS to probe biological samples involved the analysis of
S. coelicolor bacteria. This was a small study with the aim of contributing lipidomics to a deeper study
by Prof. Maggie Smith at the University of York. The aim of this study was to analyse the biological
changes which occurred in the cells when a wild strain (J1929) underwent a mutation, causing it to
lose intrinsic antibiotic resistance (DT3017), and when this mutant strain was treated to reverse this
mutation (PDT16). RNA sequencing revealed a possible change in fatty acid content between the wild
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type and mutant type and DESeq analysis revealed an 87% return to the genetic make up of the wild
type after treatment.
The TUFA/TFA ratio was used to probe changes in lipid content between the three strains of S.
coelicolor (J1929, DT3017 and PDT16). This ratio revealed similarities between the J1929 and PDT16
samples, as predicted by DESeq analysis, and differences between the J1929 and PDT16 samples, and
the DT3017 sample, as predicted by RNA sequencing. The TUFA/TFA PIR showed an increase in
unsaturated lipid content for the DT3017 sample. This confirmation by established biological techniques
confirms the ability of RS to probe accurate lipidomics from bulk bacteria samples. Future work with
these samples will involves a full Raman study, similar to that performed on the prostate cancer cells,
including PCA/LDA and full PIR analysis, to provide a more detailed biomolecular view of the mutation
and treatment described here.
These two studies taken together highlight the use of Raman spectroscopy to probe biomolecular
information from a variety of samples. The use of the TUFA/TFA ratio across both the bacteria and
prostate cancer experiments demonstrates the versatility of Raman and PIR analysis. The general
agreement between the wider, non-RS, literature and the Raman biomolecular results for the H517–15
patient sample in this study confirms that RS can be used to probe biomarkers associated with prostate
cancer to a high degree of accuracy. With the versatility and depth of analysis shown to be possible
in this thesis, Raman has the potential to change the way researchers and medical professionals study
diseases like cancer.
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